name,smiles,label100,phase,moa,drug_category
meclofenamic-acid,Cc1ccc(Cl)c(Nc2ccccc2C(O)=O)c1Cl,0,Launched,"cyclooxygenase inhibitor, prostanoid receptor antagonist",noncancer
zotepine,CN(C)CCOC1=Cc2ccccc2Sc2ccc(Cl)cc12,0,Launched,"dopamine receptor antagonist, serotonin receptor antagonist",noncancer
ranirestat,Fc1cc(Br)ccc1CN1C(=O)c2cccn2[C@@]2(CC(=O)NC2=O)C1=O,0,Phase 3,aldose reductase inhibitor,noncancer
efonidipine-monoethanolate,CCO.CC1=C(C(c2cccc(c2)[N+]([O-])=O)C(=C(C)N1)P1(=O)OCC(C)(C)CO1)C(=O)OCCN(Cc1ccccc1)c1ccccc1,1,Launched,"L-type calcium channel blocker, T-type calcium channel blocker",Unknown
chlorzoxazone,Clc1ccc2oc(=O)[nH]c2c1,0,Launched,bacterial 30S ribosomal subunit inhibitor,noncancer
A922500,OC(=O)[C@H]1CCC[C@H]1C(=O)c1ccc(cc1)-c1ccc(NC(=O)Nc2ccccc2)cc1,0,Preclinical,diacylglycerol O acyltransferase inhibitor,noncancer
PHCCC,O\N=C1/C2CC2(Oc2ccccc12)C(=O)Nc1ccccc1,0,Preclinical,glutamate receptor agonist,targeted cancer
IPI-145,C[C@H](Nc1ncnc2[nH]cnc12)c1cc2cccc(Cl)c2c(=O)n1-c1ccccc1,0,Phase 3,PI3K inhibitor,targeted cancer
evatanepag,CC(C)(C)c1ccc(CN(Cc2cccc(OCC(O)=O)c2)S(=O)(=O)c2cccnc2)cc1,0,Phase 2,prostaglandin inhibitor,noncancer
peficitinib,NC(=O)c1cnc2[nH]ccc2c1N[C@H]1[C@H]2C[C@H]3C[C@@H]1C[C@](O)(C3)C2,0,Phase 3,JAK inhibitor,noncancer
mabuterol,CC(C)(C)NCC(O)c1cc(Cl)c(N)c(c1)C(F)(F)F,0,Launched,adrenergic receptor agonist,noncancer
GSK2330672,CCCC[C@]1(CC)CS(=O)(=O)c2cc(CNC(CC(O)=O)CC(O)=O)c(OC)cc2[C@H](N1)c1ccccc1,0,Phase 2,bile acid transporter inhibitor,noncancer
diosmetin,COc1ccc(cc1O)-c1cc(=O)c2c(O)cc(O)cc2o1,0,Launched,aryl hydrocarbon receptor agonist,noncancer
isoliquiritigenin,Oc1ccc(cc1)\C=C\C(=O)c1ccc(O)cc1O,0,Preclinical,guanylate cyclase activator,targeted cancer
chlorcyclizine,CN1CCN(CC1)C(c1ccccc1)c1ccc(Cl)cc1,0,Launched,histamine receptor antagonist,noncancer
bepridil,CC(C)COCC(CN(Cc1ccccc1)c1ccccc1)N1CCCC1,0,Launched,calcium channel blocker,noncancer
nifuroxazide,Oc1ccc(cc1)C(=O)N\N=C\c1ccc(o1)[N+]([O-])=O,0,Launched,bacterial DNA inhibitor,noncancer
riodipine,COC(=O)C1=C(C)NC(C)=C(C1c1ccccc1OC(F)F)C(=O)OC,0,Phase 2,calcium channel blocker,noncancer
iopanic-acid,CCC(Cc1c(I)cc(I)c(N)c1I)C(O)=O,0,Preclinical,thyroid hormone inhibitor,noncancer
omecamtiv-mecarbil,COC(=O)N1CCN(Cc2cccc(NC(=O)Nc3ccc(C)nc3)c2F)CC1,0,Phase 2,cardiac myosin activator,noncancer
raltitrexed,CN(Cc1ccc2[nH]c(C)nc(=O)c2c1)c1ccc(s1)C(=O)N[C@@H](CCC(O)=O)C(O)=O,1,Launched,thymidylate synthase inhibitor,targeted cancer
LY2090314,Fc1cc2CN(CCn3cc(C4=C(C(=O)NC4=O)c4cnc5ccccn45)c(c1)c23)C(=O)N1CCCCC1,1,Phase 2,glycogen synthase kinase inhibitor,targeted cancer
AR-42,CC(C)[C@H](C(=O)Nc1ccc(cc1)C(=O)NO)c1ccccc1,1,Phase 1,HDAC inhibitor,targeted cancer
paclitaxel,CC(=O)O[C@@H]1C2=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C1=O)OC(C)=O)C2(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)c1ccccc1)c1ccccc1,1,Launched,tubulin polymerization inhibitor,chemo
Y-320,Cc1c(cnn1-c1ccc(Cl)cc1)C(=O)Nc1ccc(N2CCC(CC2)N2CCOCC2)c(c1)C#N,1,Preclinical,interleukin inhibitor,noncancer
beclomethasone-dipropionate,CCC(=O)OCC(=O)[C@@]1(OC(=O)CC)[C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]12C,1,Launched,glucocorticoid receptor agonist,noncancer
alclofenac,OC(=O)Cc1ccc(OCC=C)c(Cl)c1,0,Launched,cyclooxygenase inhibitor,noncancer
lenvatinib,COc1cc2nccc(Oc3ccc(NC(=O)NC4CC4)c(Cl)c3)c2cc1C(N)=O,1,Launched,"FGFR inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor",targeted cancer
elagolix,COc1cccc(c1F)-c1c(C)n(Cc2c(F)cccc2C(F)(F)F)c(=O)n(C[C@H](NCCCC(O)=O)c2ccccc2)c1=O,0,Phase 3,gonadotropin releasing factor hormone receptor antagonist,Unknown
pheniramine,CN(C)CCC(c1ccccc1)c1ccccn1,1,Launched,histamine receptor antagonist,noncancer
telotristat,Cc1ccn(n1)-c1cc(Cl)ccc1[C@@H](Oc1cc(nc(N)n1)-c1ccc(C[C@H](N)C(O)=O)cc1)C(F)(F)F,0,Launched,tryptophan hydroxylase inhibitor,noncancer
GBR-12935,C(CN1CCN(CCOC(c2ccccc2)c2ccccc2)CC1)Cc1ccccc1,0,Preclinical,dopamine uptake inhibitor,noncancer
tenofovir,C[C@H](Cn1cnc2c(N)ncnc12)OCP(O)(O)=O,0,Launched,"HIV integrase inhibitor, nucleoside reverse transcriptase inhibitor",noncancer
cloranolol,CC(C)(C)NCC(O)COc1cc(Cl)ccc1Cl,0,Launched,adrenergic receptor antagonist,noncancer
CGK-733,[O-][N+](=O)c1cc(NC(=S)NC(NC(=O)C(c2ccccc2)c2ccccc2)C(Cl)(Cl)Cl)ccc1F,0,Preclinical,"ATM kinase inhibitor, ATR kinase inhibitor",targeted cancer
armodafinil,NC(=O)C[S@@](=O)C(c1ccccc1)c1ccccc1,0,Launched,adrenergic receptor agonist,noncancer
OG-L002,N[C@H]1C[C@@H]1c1ccc(cc1)-c1cccc(O)c1,0,Preclinical,histone lysine demethylase inhibitor,noncancer
amoxapine,Clc1ccc2Oc3ccccc3N=C(N3CCNCC3)c2c1,0,Launched,norepinephrine reputake inhibitor,noncancer
SKF-38393,Oc1cc2CCNCC(c3ccccc3)c2cc1O,0,Preclinical,dopamine receptor agonist,noncancer
netupitant,CN(C(=O)C(C)(C)c1cc(cc(c1)C(F)(F)F)C(F)(F)F)c1cnc(cc1-c1ccccc1C)N1CCN(C)CC1,0,Launched,tachykinin antagonist,noncancer
mifobate,COP(=O)(OC)OC(c1ccc(Cl)cc1)P(=O)(OC)OC,0,Phase 2,PPAR receptor antagonist,noncancer
GW-583340,CS(=O)(=O)CCNCc1nc(cs1)-c1ccc2ncnc(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c2c1,1,Preclinical,EGFR inhibitor,targeted cancer
diazooxonorleucine,N[C@@H](CCC(=O)C=[N+]=N)C(O)=O,1,Phase 2,glutamate receptor antagonist,noncancer
AMN-082,C(CNC(c1ccccc1)c1ccccc1)NC(c1ccccc1)c1ccccc1,0,Preclinical,glutamate receptor modulator,noncancer
thioguanine,Nc1nc2nc[nH]c2c(=S)[nH]1,1,Launched,purine antagonist,targeted cancer
cyamemazine,CC(CN(C)C)CN1c2ccccc2Sc2ccc(cc12)C#N,0,Launched,serotonin receptor antagonist,noncancer
docetaxel,CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@]1(C)[C@@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c3ccccc3)C(C)=C([C@@H](O)C1=O)C2(C)C,1,Launched,tubulin polymerization inhibitor,chemo
isoguvacine,OC(=O)C1=CCNCC1,0,Preclinical,benzodiazepine receptor agonist,noncancer
kakonein,OCC1OC(C(O)C(O)C1O)c1c(O)ccc2c1occ(-c1ccc(O)cc1)c2=O,0,Phase 2,"GABA receptor antagonist, serotonin receptor antagonist",noncancer
tacrolimus,CO[C@@H]1C[C@@H](CC[C@H]1O)\C=C(/C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@]2(O)O[C@@H]([C@H](C[C@H]2C)OC)[C@H](C[C@@H](C)C\C(C)=C\[C@@H](CC=C)C(=O)C[C@H](O)[C@H]1C)OC,1,Launched,calcineurin inhibitor,noncancer
proxyfan,C(COCc1ccccc1)Cc1cnc[nH]1,0,Preclinical,histamine receptor modulator,noncancer
VX-765,CCO[C@H]1OC(=O)C[C@@H]1NC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)c1ccc(N)c(Cl)c1)C(C)(C)C,1,Phase 2,caspase inhibitor,noncancer
NXY-059,CC(C)(C)[N+](\[O-])=C\c1ccc(cc1S(O)(=O)=O)S(O)(=O)=O,0,Phase 3,free radical scavenger,noncancer
cytochalasin-b,C[C@H]1[C@H]2[C@H](Cc3ccccc3)NC(=O)[C@]22OC(=O)\C=C/[C@H](O)CCC[C@@H](C)C\C=C\[C@H]2[C@H](O)C1=C,1,Phase 2,microtubule inhibitor,noncancer
proxymetacaine,CCCOc1ccc(cc1N)C(=O)OCCN(CC)CC,0,Launched,sodium channel blocker,noncancer
neostigmine,CN(C)C(=O)Oc1cccc(c1)[N+](C)(C)C,0,Launched,acetylcholinesterase inhibitor,noncancer
NNC-711,OC(=O)C1=CCCN(CCON=C(c2ccccc2)c2ccccc2)C1,0,Preclinical,GABA uptake inhibitor,noncancer
doxorubicin,COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(=O)CO,1,Launched,topoisomerase inhibitor,Unknown
VLX600,C\C(=N\Nc1nnc2c(n1)[nH]c1c(C)cccc21)c1ccccn1,1,Phase 1,ubiquitin C-terminal hydrolase inhibitor,targeted cancer
rufinamide,NC(=O)c1cn(Cc2c(F)cccc2F)nn1,0,Launched,voltage-gated sodium channel blocker,noncancer
CGH2466,Nc1nc(c(s1)-c1ccncc1)-c1ccc(Cl)c(Cl)c1,0,Preclinical,adenosine receptor antagonist,noncancer
examorelin,C[C@H](NC(=O)[C@@H](Cc1c(C)[nH]c2ccccc12)NC(=O)[C@@H](N)Cc1cnc[nH]1)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@H](Cc1ccccc1)C(=O)N[C@@H](CCCCN)C(N)=O,0,Phase 2,growth hormone releasing factor agonist,noncancer
zaltidine,Cc1ncc([nH]1)-c1csc(NC(N)=N)n1,0,Phase 3,histamine receptor antagonist,noncancer
sulfathiazole,Nc1ccc(cc1)S(=O)(=O)Nc1nccs1,0,Launched,dihydropteroate synthase inhibitor,targeted cancer
ritonavir,CC(C)[C@H](NC(=O)N(C)Cc1csc(n1)C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](Cc1ccccc1)NC(=O)OCc1cncs1)Cc1ccccc1,0,Launched,HIV protease inhibitor,noncancer
chrysin,Oc1cc(O)c2c(c1)oc(cc2=O)-c1ccccc1,0,Phase 1,breast cancer resistance protein inhibitor,targeted cancer
isoflurane,FC(F)OC(Cl)C(F)(F)F,0,Launched,inhaled anaesthetic,noncancer
JNJ-17203212,FC(F)(F)c1ccc(NC(=O)N2CCN(CC2)c2ncccc2C(F)(F)F)nc1,0,Preclinical,TRPV antagonist,noncancer
pyrithyldione,CCC1(CC)C(=O)NC=CC1=O,0,Withdrawn,psychoactive drug,noncancer
tazemetostat,CCN(C1CCOCC1)c1cc(cc(C(=O)NCc2c(C)cc(C)[nH]c2=O)c1C)-c1ccc(CN2CCOCC2)cc1,1,Phase 2,histone lysine methyltransferase inhibitor,targeted cancer
tiabendazole,c1nc(cs1)-c1nc2ccccc2[nH]1,0,Launched,angiogenesis inhibitor,noncancer
oxcarbazepine,NC(=O)N1c2ccccc2CC(=O)c2ccccc12,1,Launched,sodium channel blocker,noncancer
tedizolid-phosphate,Cn1nnc(n1)-c1ccc(cn1)-c1ccc(cc1F)N1C[C@H](COP(O)(O)=O)OC1=O,1,Launched,protein synthesis inhibitor,noncancer
tripelennamine,CN(C)CCN(Cc1ccccc1)c1ccccn1,0,Launched,histamine receptor antagonist,noncancer
preladenant,COCCOc1ccc(cc1)N1CCN(CCn2ncc3c2nc(N)n2nc(nc32)-c2ccco2)CC1,0,Phase 3,adenosine receptor antagonist,targeted cancer
tucatinib,Cc1cc(Nc2ncnc3ccc(NC4=NC(C)(C)CO4)cc23)ccc1Oc1ccn2ncnc2c1,1,Phase 2,EGFR inhibitor,targeted cancer
enoxacin,CCn1cc(C(O)=O)c(=O)c2cc(F)c(nc12)N1CCNCC1,0,Launched,topoisomerase inhibitor,noncancer
RS-0481,CC(NC(=O)C1CSCN1C(=O)c1ccccc1)c1ccccc1,0,Phase 2,immunostimulant,targeted cancer
LX1031,COc1cccc(c1)-c1ccc(cc1)[C@@H](Oc1cc(nc(N)n1)-c1ccc(C[C@H](N)C(O)=O)cc1)C(F)(F)F,0,Phase 2,tryptophan hydroxylase inhibitor,noncancer
trimethobenzamide,COc1cc(cc(OC)c1OC)C(=O)NCc1ccc(OCCN(C)C)cc1,0,Launched,histamine receptor antagonist,noncancer
methiazole,COC(=O)Nc1nc2cc(SC(C)C)ccc2[nH]1,1,Preclinical,anthelmintic agent,noncancer
succinylsulfathiazole,OC(=O)CCC(=O)Nc1ccc(cc1)S(=O)(=O)Nc1nccs1,0,Phase 2,dihydrofolate reductase inhibitor,noncancer
desipramine,CNCCCN1c2ccccc2CCc2ccccc12,0,Launched,tricyclic antidepressant,noncancer
methiopril,CC1CCCC(N1C(=O)CCSC(C)=O)C(O)=O,0,Phase 2,angiotensin converting enzyme inhibitor,noncancer
nadide,NC(=O)c1ccc[n+](c1)[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OC[C@H]2O[C@H]([C@H](O)[C@@H]2O)n2cnc3c(N)ncnc23)[C@@H](O)[C@H]1O,1,Launched,electron acceptor,noncancer
dabrafenib,CC(C)(C)c1nc(c(s1)-c1ccnc(N)n1)-c1cccc(NS(=O)(=O)c2c(F)cccc2F)c1F,1,Launched,RAF inhibitor,targeted cancer
ephedrine-(racemic),CNC(C)C(O)c1ccccc1,0,Launched,adrenergic receptor agonist,noncancer
ZD-7155,CCc1cc2N(Cc3ccc(cc3)-c3ccccc3-c3nnn[nH]3)C(=O)CCc2c(CC)n1,0,Preclinical,angiotensin receptor antagonist,Unknown
ENMD-2076,CN1CCN(CC1)c1cc(Nc2cc(C)[nH]n2)nc(\C=C\c2ccccc2)n1,1,Phase 2,"Aurora kinase inhibitor, FLT3 inhibitor, VEGFR inhibitor",targeted cancer
desogestrel,CC[C@]12CC(=C)[C@H]3[C@@H](CCC4=CCCC[C@H]34)[C@@H]1CC[C@@]2(O)C#C,0,Launched,progesterone receptor agonist,noncancer
ZK811752,C[C@@H]1CN(Cc2ccc(F)cc2)CCN1C(=O)COc1ccc(Cl)cc1NC(N)=O,1,Phase 2,CC chemokine receptor antagonist,targeted cancer
sulfadoxine,COc1ncnc(NS(=O)(=O)c2ccc(N)cc2)c1OC,0,Launched,dihydropteroate synthase inhibitor,noncancer
pacritinib,C(CN1CCCC1)Oc1ccc2Nc3nccc(n3)-c3cccc(COC\C=C\COCc1c2)c3,1,Phase 3,"FLT3 inhibitor, JAK inhibitor",targeted cancer
proguanil,CC(C)NC(=N)NC(=N)Nc1ccc(Cl)cc1,0,Launched,dihydrofolate reductase inhibitor,noncancer
trichlormethiazide,NS(=O)(=O)c1cc2c(NC(NS2(=O)=O)C(Cl)Cl)cc1Cl,0,Launched,chloride channel blocker,noncancer
BU-239,C1CN=C(N1)c1cnc2ccccc2n1,0,Preclinical,"imidazoline receptor ligand, imidazoline receptor agonist",Unknown
salicylanilide,Oc1ccccc1C(=O)Nc1ccccc1,0,Preclinical,other antibiotic,Unknown
DMP-777,CCC[C@@H](NC(=O)N1[C@@H](Oc2ccc(cc2)C(=O)N2CCN(C)CC2)C(CC)(CC)C1=O)c1ccc2OCOc2c1,0,Phase 2,elastase inhibitor,Unknown
fdcyd,Nc1nc(=O)n(cc1F)[C@H]1C[C@H](O)[C@@H](CO)O1,1,Phase 2,DNA methyltransferase inhibitor,targeted cancer
losartan,CCCCc1nc(Cl)c(CO)n1Cc1ccc(cc1)-c1ccccc1-c1nnn[nH]1,0,Launched,angiotensin receptor antagonist,noncancer
fesoterodine,CC(C)N(CC[C@H](c1ccccc1)c1cc(CO)ccc1OC(=O)C(C)C)C(C)C,0,Launched,acetylcholine receptor antagonist,noncancer
pralidoxime,C[n+]1ccccc1\C=N\O,0,Launched,acetylcholinesterase inhibitor,noncancer
swainsonine,O[C@@H]1CN2CCC[C@@H](O)[C@@H]2[C@@H]1O,0,Phase 2,alpha mannosidase inhibitor,targeted cancer
entecavir,Nc1nc(=O)c2ncn([C@H]3C[C@H](O)[C@@H](CO)C3=C)c2[nH]1,0,Launched,"DNA replication inhibitor, nucleoside reverse transcriptase inhibitor",noncancer
dichlorophen,Oc1ccc(Cl)cc1Cc1cc(Cl)ccc1O,0,Launched,anticestodal agent,noncancer
PNU-142633,CNC(=O)c1ccc2[C@H](CCN3CCN(CC3)c3ccc(cc3)C(N)=O)OCCc2c1,0,Phase 2,serotonin receptor agonist,noncancer
telmisartan,CCCc1nc2c(C)cc(cc2n1Cc1ccc(cc1)-c1ccccc1C(O)=O)-c1nc2ccccc2n1C,0,Launched,angiotensin receptor antagonist,noncancer
evodiamine,CN1C2N(CCc3c2[nH]c2ccccc32)C(=O)c2ccccc12,1,Preclinical,"ATPase inhibitor, TRPV agonist",targeted cancer
dexrazoxane,C[C@@H](CN1CC(=O)NC(=O)C1)N1CC(=O)NC(=O)C1,1,Launched,"chelating agent, topoisomerase inhibitor",noncancer
palomid-529,COc1ccc(COc2cc3oc(=O)c4cc(ccc4c3cc2OC)C(C)O)cc1,1,Phase 1,"AKT inhibitor, mTOR inhibitor",targeted cancer
oxolinic-acid,CCn1cc(C(O)=O)c(=O)c2cc3OCOc3cc12,0,Preclinical,bacterial DNA gyrase inhibitor,noncancer
givinostat,CCN(CC)Cc1ccc2cc(COC(=O)Nc3ccc(cc3)C(=O)NO)ccc2c1,1,Phase 2,HDAC inhibitor,targeted cancer
SC-19220,CC(=O)NNC(=O)N1Cc2ccccc2Oc2ccc(Cl)cc12,0,Preclinical,prostanoid receptor antagonist,noncancer
etoposide-phosphate,COc1cc(cc(OC)c1OP(O)(O)=O)[C@H]1[C@@H]2[C@H](COC2=O)[C@H](O[C@@H]2O[C@@H]3CO[C@@H](C)O[C@H]3[C@H](O)[C@H]2O)c2cc3OCOc3cc12,1,Launched,topoisomerase inhibitor,chemo
ONC201,Cc1ccccc1CN1C2=NCCN2C2=C(CN(Cc3ccccc3)CC2)C1=O,1,Phase 2,"AKT inhibitor, MAP kinase inhibitor",targeted cancer
tecovirimat,FC(F)(F)c1ccc(cc1)C(=O)NN1C(=O)[C@H]2[C@H]([C@H]3C=C[C@@H]2[C@@H]2C[C@H]32)C1=O,0,Phase 3,orthopoxvirus egress inhibitor,noncancer
palovarotene,CC1(C)CCC(C)(C)c2cc(\C=C\c3ccc(cc3)C(O)=O)c(Cn3cccn3)cc12,0,Phase 2,retinoid receptor agonist,noncancer
RS-17053,CC(C)(Cc1c[nH]c2ccc(Cl)cc12)NCCOc1ccccc1OCC1CC1,1,Preclinical,adrenergic receptor antagonist,noncancer
imidacloprid,[O-][N+](=O)NC1=NCCN1Cc1ccc(Cl)nc1,0,Launched,acetylcholine receptor antagonist,noncancer
regadenoson,CNC(=O)c1cnn(c1)-c1nc(N)c2ncn([C@@H]3O[C@H](CO)C(O)C3O)c2n1,0,Launched,adenosine receptor agonist,noncancer
deracoxib,COc1ccc(cc1F)-c1cc(nn1-c1ccc(cc1)S(N)(=O)=O)C(F)F,0,Launched,cyclooxygenase inhibitor,noncancer
ripasudil,C[C@H]1CNCCCN1S(=O)(=O)c1cccc2cncc(F)c12,0,Launched,rho associated kinase inhibitor,noncancer
aceclofenac,OC(=O)COC(=O)Cc1ccccc1Nc1c(Cl)cccc1Cl,0,Launched,prostanoid receptor antagonist,noncancer
NVP-AUY922,CCNC(=O)c1noc(c1-c1ccc(CN2CCOCC2)cc1)-c1cc(C(C)C)c(O)cc1O,1,Phase 2,HSP inhibitor,targeted cancer
caffeic-acid,OC(=O)\C=C\c1ccc(O)c(O)c1,1,Preclinical,"HIV integrase inhibitor, lipoxygenase inhibitor, nitric oxide production inhibitor, tumor necrosis factor production inhibitor",noncancer
nelfinavir,Cc1c(O)cccc1C(=O)N[C@@H](CSc1ccccc1)[C@H](O)CN1C[C@H]2CCCC[C@H]2C[C@H]1C(=O)NC(C)(C)C,0,Launched,HIV protease inhibitor,noncancer
resorcinol,Oc1cccc(O)c1,0,Launched,phosphodiesterase inhibitor,noncancer
coumophos,CCOP(=S)(OCC)Oc1ccc2c(C)c(Cl)c(=O)oc2c1,0,Preclinical,cholinesterase inhibitor,noncancer
lidoflazine,Cc1cccc(C)c1NC(=O)CN1CCN(CCCC(c2ccc(F)cc2)c2ccc(F)cc2)CC1,0,Launched,calcium channel blocker,noncancer
R306465,ONC(=O)c1cnc(nc1)N1CCN(CC1)S(=O)(=O)c1ccc2ccccc2c1,1,Phase 1,HDAC inhibitor,Unknown
PHA-665752,Cc1[nH]c(\C=C2/C(=O)Nc3ccc(cc23)S(=O)(=O)Cc2c(Cl)cccc2Cl)c(C)c1C(=O)N1CCC[C@@H]1CN1CCCC1,1,Preclinical,c-Met inhibitor,targeted cancer
resibufogenin,C[C@]12CC[C@H]3[C@@H](CC[C@@H]4C[C@@H](O)CC[C@]34C)[C@]11O[C@@H]1C[C@@H]2c1ccc(=O)oc1,0,Phase 2,Na/K-ATPase inhibitor,noncancer
sodium-salicylate,OC(=O)c1ccccc1O,0,Launched,prostanoid receptor antagonist,noncancer
enilconazole,Clc1ccc(C(Cn2ccnc2)OCC=C)c(Cl)c1,0,Launched,sterol demethylase inhibitor,noncancer
dienestrol,C\C=C(c1ccc(O)cc1)\C(c1ccc(O)cc1)=C\C,0,Launched,estrogen receptor agonist,noncancer
indibulin,Clc1ccc(Cn2cc(C(=O)C(=O)Nc3ccncc3)c3ccccc23)cc1,1,Phase 1/Phase 2,tubulin polymerization inhibitor,chemo
cyclopiazonic-acid,CC(=O)C1C(=O)[C@@H]2[C@@H]3[C@@H](Cc4cccc5[nH]cc3c45)C(C)(C)N2C1=O,0,Preclinical,ATPase inhibitor,noncancer
bupranolol,Cc1ccc(Cl)c(OCC(O)CNC(C)(C)C)c1,0,Launched,adrenergic receptor antagonist,noncancer
ezutromid,CCN(CC)c1ccc(cc1)-n1nc2cc(C)c(N)cc2n1,0,Phase 2,utrophin enhancer,noncancer
KRN-633,CCCNC(=O)Nc1ccc(Oc2ncnc3cc(OC)c(OC)cc23)cc1Cl,0,Preclinical,VEGFR inhibitor,targeted cancer
eprobemide,Clc1ccc(cc1)C(=O)NCCCN1CCOCC1,1,Launched,monoamine oxidase inhibitor,noncancer
amlexanox,CC(C)c1ccc2oc3nc(N)c(cc3c(=O)c2c1)C(O)=O,0,Launched,histamine receptor modulator,noncancer
alcuronium,OC\C=C1/C[N@+]2(CC=C)CC[C@@]34[C@@H]2C[C@@H]1\C1=C\N2C5[C@]6(CC[N@@+]7(CC=C)C\C(=C/CO)[C@H](C[C@@H]67)\C5=C\N(C31)c1ccccc41)c1ccccc21,0,Launched,muscle relaxant,noncancer
nitrendipine,CCOC(=O)C1=C(C)NC(C)=C(C1c1cccc(c1)[N+]([O-])=O)C(=O)OC,0,Launched,calcium channel blocker,noncancer
rotigotine,CCCN(CCc1cccs1)[C@H]1CCc2c(O)cccc2C1,0,Launched,dopamine receptor agonist,noncancer
reserpine,CO[C@H]1[C@@H](C[C@@H]2CN3CCc4c([nH]c5cc(OC)ccc45)[C@H]3C[C@@H]2[C@@H]1C(=O)OC)OC(=O)c1cc(OC)c(OC)c(OC)c1,0,Launched,vesicular monoamine transporter inhibitor,noncancer
CS-110266,C1CCN(CC1)C1(CCCCC1)c1cc2ccccc2s1,1,Preclinical,dopamine receptor agonist,noncancer
crenolanib,CC1(COc2ccc3n(cnc3c2)-c2ccc3cccc(N4CCC(N)CC4)c3n2)COC1,1,Phase 2,PDGFR tyrosine kinase receptor inhibitor,Unknown
carbadox,COC(=O)N\N=C\c1c[n+]([O-])c2ccccc2[n+]1[O-],0,Launched,other antibiotic,noncancer
inimur,CSCC1CN(\N=C\c2ccc(o2)[N+]([O-])=O)C(=O)O1,0,Launched,other antifungal,noncancer
clenbuterol,CC(C)(C)NCC(O)c1cc(Cl)c(N)c(Cl)c1,1,Launched,adrenergic receptor agonist,noncancer
PI-828,Nc1ccc(cc1)-c1cccc2c1oc(cc2=O)N1CCOCC1,1,Preclinical,PI3K inhibitor,noncancer
ezetimibe,OC(CC[C@@H]1[C@H](N(C1=O)c1ccc(F)cc1)c1ccc(O)cc1)c1ccc(F)cc1,0,Launched,"cholesterol inhibitor, Niemann-Pick C1-like 1 protein antagonist",noncancer
pelanserin,O=c1[nH]c2ccccc2c(=O)n1CCCN1CCN(CC1)c1ccccc1,0,Phase 2,serotonin receptor antagonist,noncancer
7-nitroindazole,[O-][N+](=O)c1cccc2cn[nH]c12,1,Preclinical,nitric oxide synthase inhibitor,noncancer
azalomycin-b,CC[C@@H]1[C@@H](C)O[C@](O)(C[C@H]1O[C@H]1C[C@H](O)[C@H](O)[C@H](C)O1)[C@@H](C)[C@H](O)[C@H](C)[C@@H]1OC(=O)\C=C\C=C\[C@@H](C)[C@H](OC(=O)\C=C\C=C\[C@@H]1C)[C@@H](C)[C@@H](O)[C@H](C)[C@@]1(O)C[C@@H](O[C@H]2C[C@H](O)[C@H](O)[C@H](C)O2)[C@H](CC)[C@@H](C)O1,1,Preclinical,bacterial 50S ribosomal subunit inhibitor,Unknown
tozadenant,COc1ccc(N2CCOCC2)c2sc(NC(=O)N3CCC(C)(O)CC3)nc12,0,Phase 3,adenosine receptor antagonist,noncancer
dilazep,COc1cc(cc(OC)c1OC)C(=O)OCCCN1CCCN(CCCOC(=O)c2cc(OC)c(OC)c(OC)c2)CC1,0,Launched,adenosine reuptake inhibitor,noncancer
carmustine,[O-][N+]N(CCCl)C(=O)NCCCl,1,Launched,"DNA alkylating agent, DNA inhibitor",chemo
avasimibe,CC(C)c1cc(C(C)C)c(CC(=O)NS(=O)(=O)Oc2c(cccc2C(C)C)C(C)C)c(c1)C(C)C,0,Phase 3,ACAT inhibitor,targeted cancer
dihydroergocristine,CC(C)[C@@]1(NC(=O)[C@@H]2C[C@H]3[C@@H](Cc4c[nH]c5cccc3c45)N(C)C2)O[C@@]2(O)[C@@H]3CCCN3C(=O)[C@H](Cc3ccccc3)N2C1=O,1,Launched,"adrenergic receptor antagonist, prolactin inhibitor",noncancer
tariquidar,COc1cc2CCN(CCc3ccc(NC(=O)c4cc(OC)c(OC)cc4NC(=O)c4cnc5ccccc5c4)cc3)Cc2cc1OC,0,Phase 3,P glycoprotein inhibitor,targeted cancer
daprodustat,OC(=O)CNC(=O)C1C(=O)N(C2CCCCC2)C(=O)N(C2CCCCC2)C1=O,0,Phase 3,hypoxia inducible factor inhibitor,noncancer
tolimidone,Cc1cccc(Oc2cnc(=O)[nH]c2)c1,0,Phase 2,src activator,noncancer
pruvanserin,Fc1ccc(CCN2CCN(CC2)C(=O)c2cccc3c(c[nH]c23)C#N)cc1,0,Phase 2,serotonin receptor antagonist,noncancer
sunitinib,CCN(CC)CCNC(=O)c1c(C)[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c1C,1,Launched,"FLT3 inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, RET tyrosine kinase inhibitor, VEGFR inhibitor",targeted cancer
epirizole,COc1cc(C)nn1-c1nc(C)cc(OC)n1,0,Launched,cyclooxygenase inhibitor,noncancer
SB-225002,Oc1cc(ccc1NC(=O)Nc1ccccc1Br)[N+]([O-])=O,1,Preclinical,CC chemokine receptor antagonist,noncancer
phenprocoumon,CCC(c1ccccc1)c1c(O)c2ccccc2oc1=O,0,Launched,vitamin K antagonist,noncancer
ki16198,COC(=O)CCSCc1ccc(cc1)-c1onc(C)c1NC(=O)OC(C)c1ccccc1Cl,0,Preclinical,lipoprotein antagonist,targeted cancer
PA-824,[O-][N+](=O)c1cn2C[C@@H](COc2n1)OCc1ccc(OC(F)(F)F)cc1,0,Phase 3,nitric oxide donor,noncancer
clopamide,CC1CCCC(C)N1NC(=O)c1ccc(Cl)c(c1)S(N)(=O)=O,1,Launched,sodium/chloride cotransporter inhibitor,noncancer
progesterone,CC(=O)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C,0,Launched,progesterone receptor agonist,noncancer
LCL-161,CN[C@@H](C)C(=O)N[C@@H](C1CCCCC1)C(=O)N1CCC[C@H]1c1nc(cs1)C(=O)c1ccc(F)cc1,1,Phase 2,XIAP inhibitor,targeted cancer
INCB-003284,COc1ccc(cn1)C1(O)CCC(CC1)N1CC[C@H](C1)NC(=O)CNC(=O)c1cccc(c1)C(F)(F)F,0,Phase 2,CC chemokine receptor antagonist,Unknown
fenoterol,CC(Cc1ccc(O)cc1)NCC(O)c1cc(O)cc(O)c1,0,Withdrawn,adrenergic receptor agonist,noncancer
CS-917,CC(C)Cc1sc(N)nc1-c1ccc(o1)P(O)(O)=O,0,Phase 2,fructose biphosphate inhibitor,noncancer
G-1,CC(=O)c1ccc2N[C@H]([C@H]3CC=C[C@H]3c2c1)c1cc2OCOc2cc1Br,1,Preclinical,G protein-coupled receptor agonist,targeted cancer
acyclovir,Nc1nc2n(COCCO)cnc2c(=O)[nH]1,0,Launched,DNA polymerase inhibitor,noncancer
daphnetin,Oc1ccc2ccc(=O)oc2c1O,0,Preclinical,protein kinase inhibitor,targeted cancer
ICI-63197,CCCn1c2nc(N)nn2cc(C)c1=O,0,Preclinical,phosphodiesterase inhibitor,noncancer
cephalosporin-c-zn,CC(=O)OCC1=C2N3C(SC1)[C@H](NC(=O)CCCC(N)C(=O)O[Zn]OC2=O)C3=O,0,Preclinical,bacterial cell wall synthesis inhibitor,noncancer
methylprednisolone,C[C@H]1C[C@H]2[C@@H]3CC[C@](O)(C(=O)CO)[C@@]3(C)C[C@H](O)[C@@H]2[C@@]2(C)C=CC(=O)C=C12,1,Launched,glucocorticoid receptor agonist,noncancer
mafenide,NCc1ccc(cc1)S(N)(=O)=O,0,Launched,carbonic anhydrase inhibitor,noncancer
lincomycin,CCC[C@@H]1C[C@H](N(C)C1)C(=O)N[C@H]([C@@H](C)O)[C@H]1O[C@H](SC)[C@H](O)[C@@H](O)[C@@H]1O,0,Launched,bacterial 30S ribosomal subunit inhibitor,noncancer
luteolin,Oc1cc(O)c2c(c1)oc(cc2=O)-c1ccc(O)c(O)c1,0,Phase 2,glucosidase inhibitor,noncancer
rubitecan,CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4cccc([N+]([O-])=O)c4cc3Cn1c2=O,1,Phase 3,topoisomerase inhibitor,chemo
CGP-13501,CC(C)(Cc1cc(c(O)c(c1)C(C)(C)C)C(C)(C)C)C=O,0,Preclinical,GABA receptor modulator,noncancer
metoxibutropate,COc1ccccc1OC(=O)C(C)c1ccc(CC(C)C)cc1,1,Launched,cyclooxygenase inhibitor,noncancer
adenosine-phosphate,Nc1ncnc2n(cnc12)C1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O,0,Launched,adenosine receptor agonist,targeted cancer
WAY-161503,Clc1cc2NC(=O)C3CNCCN3c2cc1Cl,0,Preclinical,serotonin receptor agonist,noncancer
solithromycin,CC[C@H]1OC(=O)[C@@](C)(F)C(=O)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@@](C)(C[C@@H](C)C(=O)[C@H](C)[C@H]2N(CCCCn3cc(nn3)-c3cccc(N)c3)C(=O)O[C@]12C)OC,0,Phase 3,protein synthesis inhibitor,noncancer
acetylcysteine,CC(=O)N[C@@H](CS)C(O)=O,1,Launched,mucolytic agent,noncancer
ML347,COc1ccc(cc1)-c1cnc2c(cnn2c1)-c1cccc2ncccc12,0,Preclinical,ALK tyrosine kinase receptor inhibitor,targeted cancer
PF-573228,CS(=O)(=O)c1cccc(CNc2nc(Nc3ccc4NC(=O)CCc4c3)ncc2C(F)(F)F)c1,1,Preclinical,focal adhesion kinase inhibitor,targeted cancer
procysteine,OC(=O)[C@@H]1CSC(=O)N1,0,Phase 3,glutathione synthase stimulant,noncancer
fenbufen,OC(=O)CCC(=O)c1ccc(cc1)-c1ccccc1,0,Launched,cyclooxygenase inhibitor,noncancer
CGP-7930,CC(C)(CO)Cc1cc(c(O)c(c1)C(C)(C)C)C(C)(C)C,0,Preclinical,GABA receptor modulator,noncancer
ZM-226600,CC(O)(C(=O)Nc1ccc(cc1)S(=O)(=O)c1ccccc1)C(F)(F)F,0,Preclinical,Kir6 channel (KATP) activator,noncancer
deptropine,CN1[C@H]2CC[C@@H]1CC(C2)OC1c2ccccc2CCc2ccccc12,0,Preclinical,histamine receptor antagonist,noncancer
teroxirone,O=c1n(CC2CO2)c(=O)n(CC2CO2)c(=O)n1CC1CO1,1,Phase 1,DNA inhibitor,chemo
viloxazine,CCOc1ccccc1OCC1CNCCO1,0,Launched,norepinephrine reuptake inhibitor,noncancer
sodium-oxybate,OCCCC(O)=O,0,Launched,benzodiazepine receptor agonist,Unknown
timolol,CC(C)(C)NC[C@@H](O)COc1nsnc1N1CCOCC1,0,Launched,adrenergic receptor antagonist,noncancer
tranilast,COc1ccc(\C=C\C(=O)Nc2ccccc2C(O)=O)cc1OC,1,Launched,angiogenesis inhibitor,noncancer
usniacin-(+),CC(=O)C1C(=O)C=C2Oc3c(c(O)c(C)c(O)c3C(C)=O)[C@@]2(C)C1=O,1,Preclinical,MAP kinase activator,targeted cancer
SB-939,CCCCc1nc2cc(ccc2n1CCN(CC)CC)\C=C\C(=O)NO,1,Phase 2,HDAC inhibitor,targeted cancer
desvenlafaxine,CN(C)CC(c1ccc(O)cc1)C1(O)CCCCC1,0,Launched,serotonin-norepinephrine reuptake inhibitor (SNRI),noncancer
lorcaserin,C[C@H]1CNCCc2ccc(Cl)cc12,0,Launched,serotonin receptor agonist,noncancer
fenoldopam,Oc1ccc(cc1)C1CNCCc2c(Cl)c(O)c(O)cc12,0,Launched,dopamine receptor agonist,noncancer
pritelivir,CN(C(=O)Cc1ccc(cc1)-c1ccccn1)c1nc(C)c(s1)S(N)(=O)=O,0,Phase 2,helicase primase inhibitor,noncancer
guanadrel,NC(=N)NCC1COC2(CCCCC2)O1,0,Launched,adrenergic inhibitor,noncancer
2-hydroxyflutamide,CC(C)(O)C(=O)Nc1ccc(c(c1)C(F)(F)F)[N+]([O-])=O,0,Phase 1/Phase 2,androgen receptor antagonist,targeted cancer
alpha-methylhistamine-dihydrobromide-(S)-(+),C[C@H](N)Cc1c[nH]cn1,0,Preclinical,histamine receptor agonist,noncancer
myricitrin,C[C@@H]1O[C@@H](Oc2c(oc3cc(O)cc(O)c3c2=O)-c2cc(O)c(O)c(O)c2)[C@@H](O)[C@H](O)[C@H]1O,0,Preclinical,PKC inhibitor,noncancer
RTA-408,CC(F)(F)C(=O)N[C@]12CCC(C)(C)C[C@H]1[C@H]1C(=O)C=C3[C@@]4(C)C=C(C#N)C(=O)C(C)(C)[C@@H]4CC[C@@]3(C)[C@]1(C)CC2,0,Phase 2,nitric oxide production inhibitor,Unknown
amisulpride,CCN1CCCC1CNC(=O)c1cc(c(N)cc1OC)S(=O)(=O)CC,1,Launched,dopamine receptor antagonist,noncancer
N-methyllidocaine-iodide,CC[N+](C)(CC)CC(=O)Nc1c(C)cccc1C,0,Preclinical,antiarrhythmic medication,noncancer
pasiniazid,NNC(=O)c1ccncc1,0,Launched,cyclooxygenase inhibitor,noncancer
teriflunomide,CC(=O)C(C#N)C(=O)Nc1ccc(cc1)C(F)(F)F,1,Launched,dihydroorotate dehydrogenase inhibitor,noncancer
N-acetylglycyl-D-glutamic-acid,CC(=O)NCC(=O)N[C@H](CCC(O)=O)C(O)=O,0,Preclinical,glutamate receptor agonist,noncancer
piclamilast,COc1ccc(cc1OC1CCCC1)C(=O)Nc1c(Cl)cncc1Cl,0,Phase 2,phosphodiesterase inhibitor,noncancer
1-acetyl-4-methylpiperazine,CN1CCN(CC1)C(C)=O,0,Preclinical,acetylcholine receptor agonist,noncancer
thiamet-g,CCNC1=N[C@H]2[C@H](O[C@H](CO)[C@@H](O)[C@@H]2O)S1,0,Preclinical,GLCNAC phosphotransferase inhibitor,noncancer
tryptanthrin,O=C1c2ccccc2-n2c1nc1ccccc1c2=O,1,Preclinical,cyclooxygenase inhibitor,targeted cancer
sclareolide,C[C@@]12CC[C@H]3C(C)(C)CCC[C@]3(C)[C@H]1CC(=O)O2,0,Launched,other antifungal,noncancer
mephenesin,Cc1ccccc1OCC(O)CO,0,Launched,muscle relaxant,noncancer
merbarone,O=C(Nc1ccccc1)C1C(=O)NC(=S)NC1=O,0,Phase 2,topoisomerase inhibitor,chemo
vincristine,CC[C@]1(O)C[C@@H]2C[N@](C1)CCc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C=O)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](OC(C)=O)[C@]1(O)C(=O)OC,1,Launched,tubulin polymerization inhibitor,chemo
PF-05190457,Cc1cn2cc(CC(=O)N3CCC4(CN(C4)[C@@H]4CCc5cc(ccc45)-c4cc(C)ncn4)CC3)nc2s1,0,Phase 2,growth hormone secretagogue receptor inverse agonist,noncancer
LY2606368,COc1cccc(OCCCN)c1-c1cc(Nc2cnc(cn2)C#N)n[nH]1,1,Phase 2,CHK inhibitor,targeted cancer
glafenine,OCC(O)COC(=O)c1ccccc1Nc1ccnc2cc(Cl)ccc12,0,Withdrawn,DeltaF508-CFTR Correctors,noncancer
antazoline,C(N(Cc1ccccc1)c1ccccc1)C1=NCCN1,0,Launched,antihistamine,Unknown
eugenol,COc1cc(CC=C)ccc1O,0,Launched,androgen receptor antagonist,noncancer
sipatrigine,CN1CCN(CC1)c1ncc(c(N)n1)-c1cc(Cl)cc(Cl)c1Cl,0,Phase 2,voltage-gated sodium channel blocker,noncancer
aprepitant,C[C@H](O[C@H]1OCCN(Cc2n[nH]c(=O)[nH]2)[C@H]1c1ccc(F)cc1)c1cc(cc(c1)C(F)(F)F)C(F)(F)F,0,Launched,tachykinin antagonist,noncancer
OTX015,Cc1sc-2c(c1C)C(=N[C@@H](CC(=O)Nc1ccc(O)cc1)c1nnc(C)n-21)c1ccc(Cl)cc1,1,Phase 1/Phase 2,bromodomain inhibitor,targeted cancer
sildenafil,CCCc1nn(C)c2c1nc([nH]c2=O)-c1cc(ccc1OCC)S(=O)(=O)N1CCN(C)CC1,0,Launched,phosphodiesterase inhibitor,noncancer
ketoconazole,CC(=O)N1CCN(CC1)c1ccc(OC[C@H]2CO[C@@](Cn3ccnc3)(O2)c2ccc(Cl)cc2Cl)cc1,1,Launched,sterol demethylase inhibitor,noncancer
quinidine,COc1ccc2nccc([C@H](O)[C@H]3C[C@@H]4CC[N@]3C[C@@H]4C=C)c2c1,1,Launched,sodium channel blocker,noncancer
alfacalcidol,CC(C)CCC[C@@H](C)[C@H]1CC[C@@H]2[C@]1(C)CCC\C2=C/C=C1/C[C@@H](O)C[C@H](O)C1=C,1,Launched,vitamin D receptor agonist,noncancer
combretastatin-A-4,COc1ccc(cc1O)\C=C/c1cc(OC)c(OC)c(OC)c1,1,Phase 2,tubulin polymerization inhibitor,chemo
8-hydroxy-PIPAT,CCCN(C\C=C\I)C1CCc2cccc(O)c2C1,1,Preclinical,dopamine receptor ligand,noncancer
lestaurtinib,C[C@]12OC(C[C@]1(O)CO)n1c3ccccc3c3c4C(=O)NCc4c4c5ccccc5n2c4c13,1,Phase 3,"FLT3 inhibitor, growth factor receptor inhibitor, JAK inhibitor",Unknown
MK-2206,NC1(CCC1)c1ccc(cc1)-c1nc2ccn3c(n[nH]c3=O)c2cc1-c1ccccc1,1,Phase 2,AKT inhibitor,targeted cancer
sal003,Clc1ccc(cc1)NC(=S)NC(C(Cl)(Cl)Cl)NC(=O)\C=C\c1ccccc1,0,Preclinical,eukaryotic translation initiation factor inhibitor,noncancer
10-DEBC,CCN(CC)CCCCN1c2ccccc2Oc2ccc(Cl)cc12,0,Preclinical,AKT inhibitor,targeted cancer
danirixin,Cc1c(F)cccc1NC(=O)Nc1ccc(Cl)c(c1O)S(=O)(=O)[C@H]1CCCNC1,0,Phase 2,CC chemokine receptor antagonist,noncancer
saclofen,NCC(CS(O)(=O)=O)c1ccc(Cl)cc1,0,Preclinical,GABA receptor antagonist,noncancer
PRX-08066,Fc1ccc(CN2CCC(CC2)Nc2ncnc3sc(Cl)cc23)cc1C#N,0,Phase 2,serotonin receptor antagonist,noncancer
gefitinib,COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1,1,Launched,EGFR inhibitor,targeted cancer
adapalene,COc1ccc(cc1C12CC3CC(CC(C3)C1)C2)-c1ccc2cc(ccc2c1)C(O)=O,1,Launched,retinoid receptor agonist,noncancer
abafungin,Cc1ccc(Oc2ccccc2-c2csc(N=C3NCCCN3)n2)c(C)c1,0,Phase 3,sterol methyltransferase inhibitor,noncancer
cutamesine,COc1ccc(CCN2CCN(CCCc3ccccc3)CC2)cc1OC,0,Phase 2,sigma receptor agonist,noncancer
tamibarotene,CC1(C)CCC(C)(C)c2cc(NC(=O)c3ccc(cc3)C(O)=O)ccc12,1,Launched,retinoid receptor agonist,targeted cancer
OSI-027,COc1cccc2cc([nH]c12)-c1nc([C@H]2CC[C@@H](CC2)C(O)=O)n2ncnc(N)c12,1,Phase 1,mTOR inhibitor,targeted cancer
acetyl-farnesyl-cysteine,CC(=O)N[C@@H](CSC\C=C(/C)CC\C=C(/C)CCC=C(C)C)C(O)=O,0,Launched,methyltransferase inhibitor,noncancer
brefeldin-a,C[C@H]1CCC\C=C\[C@@H]2C[C@H](O)C[C@H]2[C@H](O)\C=C\C(=O)O1,1,Preclinical,protein synthesis inhibitor,Unknown
dehydroepiandrosterone,C[C@]12CC[C@H]3[C@@H](CC=C4C[C@@H](O)CC[C@]34C)[C@@H]1CCC2=O,0,Launched,protein synthesis stimulant,targeted cancer
ardeparin,CC(=O)NC1C(O)OC(COS(O)(=O)=O)C(OC2OC(C(OC3OC(CO)C(OC4OC(C(O)C(O)C4OS(O)(=O)=O)C(O)=O)C(OS(O)(=O)=O)C3NS(O)(=O)=O)C(O)C2OS(O)(=O)=O)C(O)=O)C1O,0,Withdrawn,thrombin inhibitor,noncancer
gidazepam,NNC(=O)CN1c2ccc(Br)cc2C(=NCC1=O)c1ccccc1,1,Launched,GABA benzodiazepine site receptor agonist,noncancer
hydroxyprogesterone,CC(=O)[C@@]1(O)CCC2C3CCC4=CC(=O)CC[C@]4(C)C3CC[C@]12C,0,Launched,progesterone receptor agonist,noncancer
NSC-319726,C\C(c1ccccn1)=N/NC(=S)N1CCC1,1,Preclinical,p53 activator,Unknown
molidustat,O=c1c(c[nH]n1-c1cc(ncn1)N1CCOCC1)-n1ccnn1,0,Phase 2,hypoxia inducible factor inhibitor,noncancer
cilengitide,CC(C)[C@@H]1N(C)C(=O)[C@@H](Cc2ccccc2)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CCCNC(N)=N)NC1=O,0,Phase 3,integrin antagonist,targeted cancer
U-50488-(-),CN([C@H]1CCCC[C@@H]1N1CCCC1)C(=O)Cc1ccc(Cl)c(Cl)c1,0,Preclinical,opioid receptor agonist,noncancer
quizartinib,CC(C)(C)c1cc(NC(=O)Nc2ccc(cc2)-c2cn3c(n2)sc2cc(OCCN4CCOCC4)ccc32)no1,1,Phase 3,FLT3 inhibitor,targeted cancer
tyrphostin-AG-879,CC(C)(C)c1cc(cc(c1O)C(C)(C)C)\C=C(/C#N)C(N)=S,0,Preclinical,tyrosine kinase inhibitor,targeted cancer
BRD4770,COC(=O)c1ccc2n(CCCc3ccccc3)c(NC(=O)c3ccccc3)nc2c1,0,Preclinical,histone lysine methyltransferase inhibitor,targeted cancer
piketoprofen,CC(C(=O)Nc1cc(C)ccn1)c1cccc(c1)C(=O)c1ccccc1,0,Launched,cyclooxygenase inhibitor,noncancer
ciprofloxacin,OC(=O)c1cn(C2CC2)c2cc(N3CCNCC3)c(F)cc2c1=O,0,Launched,bacterial DNA gyrase inhibitor,noncancer
penciclovir,Nc1nc(O)c2ncn(CCC(CO)CO)c2n1,0,Launched,DNA directed DNA polymerase inhibitor,noncancer
lapatinib,CS(=O)(=O)CCNCc1ccc(o1)-c1ccc2ncnc(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c2c1,1,Launched,EGFR inhibitor,targeted cancer
estradiol-acetate,CC(=O)Oc1ccc2[C@H]3CC[C@]4(C)[C@@H](O)CC[C@H]4[C@@H]3CCc2c1,0,Launched,estrogen receptor agonist,noncancer
hydroxyfasudil,Oc1nccc2c(cccc12)S(=O)(=O)N1CCCNCC1,0,Preclinical,rho associated kinase inhibitor,noncancer
IOX2,OC(=O)CNC(=O)c1c(O)c2ccccc2n(Cc2ccccc2)c1=O,0,Preclinical,hypoxia inducible factor inhibitor,noncancer
estrone,C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CCC2=O,1,Launched,"estrogen receptor agonist, estrogenic hormone",noncancer
compound-w,OC(=O)c1cc(Oc2ccc(cc2)[N+]([O-])=O)cc(Oc2ccc(cc2)[N+]([O-])=O)c1,0,Preclinical,beta-secretase inhibitor,noncancer
sonidegib,C[C@H]1CN(C[C@@H](C)O1)c1ccc(NC(=O)c2cccc(-c3ccc(OC(F)(F)F)cc3)c2C)cn1,1,Launched,smoothened receptor antagonist,targeted cancer
PIK-293,Cc1ccccc1-n1c(Cn2ncc3c(N)ncnc23)nc2cccc(C)c2c1=O,0,Preclinical,PI3K inhibitor,targeted cancer
PRT062070,CCS(=O)(=O)N1CCN(CC1)c1ccc(Nc2ncc(C(N)=O)c(NC3CC3)n2)cc1,1,Phase 1,"JAK inhibitor, syk inhibitor",targeted cancer
PHT-427,CCCCCCCCCCCCc1ccc(cc1)S(=O)(=O)Nc1nncs1,0,Preclinical,"AKT inhibitor, pyruvate dehydrogenase inhibitor",targeted cancer
CGP-52411,O=C1NC(=O)c2cc(Nc3ccccc3)c(Nc3ccccc3)cc12,1,Preclinical,EGFR inhibitor,targeted cancer
ozolinone,CN1C(=O)C(S\C1=C/C(O)=O)N1CCCCC1,0,Phase 3,diuretic,noncancer
ETP-46464,CC(C)(C#N)c1ccc(cc1)N1C(=O)OCc2cnc3ccc(cc3c12)-c1cnc2ccccc2c1,1,Preclinical,ATR kinase inhibitor,targeted cancer
icaritin,COc1ccc(cc1)-c1oc2c(CC=C(C)C)c(O)cc(O)c2c(=O)c1O,0,Phase 2,PPAR receptor antagonist,targeted cancer
repsox,Cc1cccc(n1)-c1n[nH]cc1-c1ccc2ncccc2n1,1,Preclinical,TGF beta receptor inhibitor,noncancer
dacinostat,OCCN(CCc1c[nH]c2ccccc12)Cc1ccc(\C=C\C(=O)NO)cc1,1,Phase 1,HDAC inhibitor,Unknown
flumequine,CC1CCc2cc(F)cc3c2n1cc(C(O)=O)c3=O,0,Launched,topoisomerase inhibitor,noncancer
fosaprepitant-dimeglumine,C[C@@H](O[C@H]1OCCN(Cc2nn(c(=O)[nH]2)P(O)(O)=O)[C@H]1c1ccc(F)cc1)c1cc(cc(c1)C(F)(F)F)C(F)(F)F,0,Launched,tachykinin antagonist,noncancer
ursolic-acid,C[C@@H]1CC[C@@]2(CC[C@]3(C)C(=CC[C@@H]4[C@@]5(C)CC[C@H](O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]2[C@H]1C)C(O)=O,0,Phase 1,"ATPase inhibitor, NFkB pathway inhibitor, STAT inhibitor",targeted cancer
3-bromopyruvate,OC(=O)C(=O)CBr,0,Preclinical,hexokinase inhibitor,targeted cancer
oprozomib,COC[C@H](NC(=O)[C@H](COC)NC(=O)c1cnc(C)s1)C(=O)N[C@@H](Cc1ccccc1)C(=O)C1(C)CO1,1,Phase 1/Phase 2,proteasome inhibitor,Unknown
BMY-14802,OC(CCCN1CCN(CC1)c1ncc(F)cn1)c1ccc(F)cc1,0,Phase 2,sigma receptor antagonist,noncancer
eupatilin,COc1ccc(cc1OC)-c1cc(=O)c2c(O)c(OC)c(O)cc2o1,0,Launched,mucus protecting agent,targeted cancer
beta-CCB,CCCCOC(=O)c1cc2c(cn1)[nH]c1ccccc21,0,Launched,benzodiazepine receptor ligand,noncancer
MDL-72832,O=C1CC2(CCCC2)CC(=O)N1CCCCNCC1COc2ccccc2O1,0,Preclinical,serotonin receptor agonist,noncancer
bay-w-9798,COC(=O)C1=C(C)N(C)C(C)=C(C1c1ccc(cc1)C(F)(F)F)C(=O)OC,0,Phase 2,antioxidant,targeted cancer
adaprev,OC1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H](O)[C@H]1O,1,Phase 3,TGF beta receptor inhibitor,noncancer
ofloxacin,CC1COc2c(N3CCN(C)CC3)c(F)cc3c2n1cc(C(O)=O)c3=O,0,Launched,bacterial DNA gyrase inhibitor,noncancer
VU0238429,COc1ccc(CN2C(=O)C(=O)c3cc(OC(F)(F)F)ccc23)cc1,1,Preclinical,acetylcholine receptor allosteric modulator,noncancer
tremorine,C(C#CCN1CCCC1)N1CCCC1,1,Preclinical,acetylcholine receptor agonist,noncancer
doxycycline,C[C@@H]1[C@H]2[C@H](O)[C@H]3[C@H](N(C)C)C(=O)C(C(N)=O)C(=O)[C@@]3(O)C(=O)C2C(=O)c2c(O)cccc12,1,Launched,metalloproteinase inhibitor,noncancer
anamorelin,CN(C)N(C)C(=O)[C@@]1(Cc2ccccc2)CCCN(C1)C(=O)[C@@H](Cc1c[nH]c2ccccc12)NC(=O)C(C)(C)N,0,Phase 3,growth hormone secretagogue receptor agonist,targeted cancer
DRF053-(R),CC[C@H](CO)Nc1nc(Nc2cccc(c2)-c2ccccn2)c2ncn(C(C)C)c2n1,0,Preclinical,CDK inhibitor,targeted cancer
TG-003,CCN1\C(Sc2ccc(OC)cc12)=C\C(C)=O,0,Preclinical,CLK inhibitor,targeted cancer
GW-842166,FC(F)(F)c1nc(Nc2ccc(Cl)cc2Cl)ncc1C(=O)NCC1CCOCC1,1,Phase 2,cannabinoid receptor agonist,noncancer
alpha-methylhistamine-dihydrobromide-(R)-(-),C[C@@H](N)Cc1c[nH]cn1,0,Preclinical,histamine receptor agonist,noncancer
serotonin,NCCc1c[nH]c2ccc(O)cc12,0,Launched,growth factor receptor activator,noncancer
temazepam,CN1c2ccc(Cl)cc2C(=NC(O)C1=O)c1ccccc1,1,Withdrawn,benzodiazepine receptor agonist,noncancer
3-alpha-bis-(4-fluorophenyl)-methoxytropane,CN1C2CCC1CC(C2)OC(c1ccc(F)cc1)c1ccc(F)cc1,0,Preclinical,dopamine uptake inhibitor,noncancer
ramelteon,CCC(=O)NCC[C@@H]1CCc2ccc3OCCc3c12,0,Launched,melatonin receptor agonist,noncancer
sarafloxacin,OC(=O)c1cn(-c2ccc(F)cc2)c2cc(N3CCNCC3)c(F)cc2c1=O,1,Launched,bacterial DNA gyrase inhibitor,noncancer
gaboxadol,Oc1noc2CNCCc12,0,Phase 3,benzodiazepine receptor agonist,noncancer
molindone,CCc1c(C)[nH]c2CCC(CN3CCOCC3)C(=O)c12,0,Launched,dopamine receptor antagonist,noncancer
piroximone,CCc1[nH]c(O)nc1C(=O)c1ccncc1,0,Phase 2,phosphodiesterase inhibitor,noncancer
masitinib,CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nc(cs3)-c3cccnc3)c2)CC1,1,Launched,"KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, src inhibitor",noncancer
LY2140023,N[C@]1(CS(=O)(=O)[C@H]2[C@@H]([C@@H]12)C(O)=O)C(O)=O,0,Phase 3,glutamate receptor agonist,noncancer
sulfinpyrazone,O=C1C(CCS(=O)c2ccccc2)C(=O)N(N1c1ccccc1)c1ccccc1,0,Launched,uricosuric blocker,noncancer
VX-745,Fc1ccc(Sc2ccc3c(-c4c(Cl)cccc4Cl)c(=O)ncn3n2)c(F)c1,0,Phase 2,p38 MAPK inhibitor,targeted cancer
istaroxime,C[C@]12CC[C@H]3[C@@H](CC(=O)[C@H]4C\C(CC[C@]34C)=N\OCCN)[C@@H]1CCC2=O,0,Phase 2,ATPase inhibitor,noncancer
dihydroartemisinin,C[C@@H]1CC[C@H]2[C@@H](C)[C@@H](O)O[C@@H]3O[C@@]4(C)CC[C@@H]1[C@@]23OO4,1,Launched,antimalarial agent,noncancer
aminosalicylate,Nc1ccc(C(O)=O)c(O)c1,0,Launched,cyclooxygenase inhibitor,noncancer
sinomenine,COC1=C[C@@H]2[C@@H]3Cc4ccc(OC)c(O)c4[C@]2(CCN3C)CC1=O,0,Preclinical,angiogenesis inhibitor,Unknown
avibactam,NC(=O)[C@@H]1CC[C@@H]2CN1C(=O)N2OS(O)(=O)=O,0,Launched,beta lactamase inhibitor,noncancer
RU-28318,CCC[C@@H]1CC2=CC(=O)CC[C@]2(C)[C@H]2CC[C@@]3(C)[C@@H](CC[C@@]3(O)CCC(O)=O)[C@H]12,0,Phase 2,cytochrome P450 inhibitor,noncancer
RS-127445,CC(C)c1cc(nc(N)n1)-c1ccc(F)c2ccccc12,0,Phase 1,serotonin receptor antagonist,noncancer
RG4733,CC(C)(C(=O)NCC(F)(F)C(F)(F)F)C(=O)N[C@H]1c2ccccc2-c2ccccc2NC1=O,0,Phase 2,gamma secretase inhibitor,targeted cancer
bepotastine,OC(=O)CCCN1CCC(CC1)O[C@@H](c1ccc(Cl)cc1)c1ccccn1,0,Launched,histamine receptor antagonist,Unknown
ropivacaine,CCCN1CCCC[C@H]1C(=O)Nc1c(C)cccc1C,0,Launched,sodium channel blocker,noncancer
gabapentin-enacarbil,CC(C)C(=O)OC(C)OC(=O)NCC1(CC(O)=O)CCCCC1,0,Launched,adrenergic receptor agonist,noncancer
SANT-1,Cc1nn(c(C)c1\C=N\N1CCN(Cc2ccccc2)CC1)-c1ccccc1,0,Preclinical,smoothened receptor antagonist,Unknown
etofylline,Cn1c2ncn(CCO)c2c(=O)n(C)c1=O,0,Launched,adenosine receptor antagonist,noncancer
CPI-613,OC(=O)CCCCC(CCSCc1ccccc1)SCc1ccccc1,0,Phase 2,pyruvate dehydrogenase inhibitor,targeted cancer
phenolphthalein,Oc1ccc(cc1)C1(OC(=O)c2ccccc12)c1ccc(O)cc1,0,Withdrawn,indicator dye,noncancer
lasalocid,CC[C@H](C1OC(CC)(C[C@@H]1C)C1CC[C@](O)(CC)[C@H](C)O1)C(=O)C(C)[C@@H](O)[C@H](C)CCc1ccc(C)c(O)c1C(O)=O,1,Launched,bacterial permeability inducer,noncancer
GW-441756,Cn1cc(\C=C2/C(=O)Nc3cccnc23)c2ccccc12,1,Preclinical,growth factor receptor inhibitor,targeted cancer
piceatannol,Oc1cc(O)cc(c1)\C=C\c1ccc(O)c(O)c1,0,Preclinical,SYK inhibitor,noncancer
SB-415286,Oc1ccc(NC2=C(C(=O)NC2=O)c2ccccc2[N+]([O-])=O)cc1Cl,0,Preclinical,glycogen synthase kinase inhibitor,noncancer
5-aminolevulinic-acid,NCC(=O)CCC(O)=O,0,Launched,oxidizing agent,targeted cancer
quinpirol-(-),CCCN1CCC[C@@H]2Cc3n[nH]cc3C[C@@H]12,0,Phase 2,dopamine receptor agonist,noncancer
rivaroxaban,Clc1ccc(s1)C(=O)NC[C@H]1CN(C(=O)O1)c1ccc(cc1)N1CCOCC1=O,0,Launched,coagulation factor inhibitor,noncancer
nobiletin,COc1ccc(cc1OC)-c1cc(=O)c2c(OC)c(OC)c(OC)c(OC)c2o1,1,Preclinical,MEK inhibitor,targeted cancer
maprotiline,CNCCCC12CCC(c3ccccc13)c1ccccc21,1,Launched,"norepinephrine reputake inhibitor, tricyclic antidepressant",noncancer
lirimilast,CS(=O)(=O)Oc1ccc2c(NC(N)=O)c(oc2c1)C(=O)c1ccc(Cl)cc1Cl,0,Phase 2,phosphodiesterase inhibitor,noncancer
vancomycin,CN[C@H](CC(C)C)C(=O)N[C@@H]1[C@H](O)c2ccc(Oc3cc4cc(Oc5ccc(cc5Cl)[C@@H](O)[C@@H]5NC(=O)[C@H](NC(=O)[C@@H]4NC(=O)[C@H](CC(N)=O)NC1=O)c1ccc(O)c(c1)-c1c(O)cc(O)cc1[C@H](NC5=O)C(O)=O)c3O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1)c(Cl)c2,0,Launched,bacterial cell wall synthesis inhibitor,noncancer
tozasertib,CN1CCN(CC1)c1cc(Nc2cc(C)[nH]n2)nc(Sc2ccc(NC(=O)C3CC3)cc2)n1,1,Phase 2,"Aurora kinase inhibitor, Bcr-Abl kinase inhibitor, FLT3 inhibitor, JAK inhibitor",targeted cancer
guvacine,OC(=O)C1=CCCNC1,0,Preclinical,GABA uptake inhibitor,noncancer
AZD1480,C[C@H](Nc1ncc(Cl)c(Nc2cc(C)[nH]n2)n1)c1ncc(F)cn1,1,Phase 1,JAK inhibitor,targeted cancer
goserelin-acetate,CC(C)C[C@H](NC(=O)[C@@H](COC(C)(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@@H]1CCC(=O)N1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1CCC[C@H]1C(=O)NNC(N)=O,0,Launched,gonadotropin releasing factor hormone receptor agonist,Unknown
fusidic-acid,C[C@@H]1[C@H](O)CC[C@@]2(C)[C@H]1CC[C@@]1(C)C2[C@H](O)C[C@@H]2[C@]1(C)C[C@H](OC(C)=O)\C2=C(/CCC=C(C)C)C(O)=O,0,Launched,bacterial 30S ribosomal subunit inhibitor,noncancer
NMS-E973,CN1CCC(CC1)NC(=O)c1cc(on1)-c1c(O)cc(O)cc1Oc1ccc(cc1)[N+]([O-])=O,1,Preclinical,HSP inhibitor,targeted cancer
1-EBIO,CCn1c2ccccc2[nH]c1=O,0,Preclinical,potassium channel activator,noncancer
pantothenic-acid,CC(C)(CO)[C@@H](O)C(=O)NCCC(O)=O,0,Launched,coenzyme A precursor,noncancer
oxandrolone,C[C@]1(O)CC[C@H]2[C@@H]3CC[C@H]4CC(=O)OC[C@]4(C)[C@H]3CC[C@]12C,0,Launched,androgen receptor agonist,noncancer
pyridoxine,Cc1ncc(CO)c(CO)c1O,0,Launched,vitamin B,noncancer
esmolol,COC(=O)CCc1ccc(OCC(O)CNC(C)C)cc1,0,Launched,adrenergic receptor antagonist,noncancer
calcipotriol,C[C@H](\C=C\[C@@H](O)C1CC1)[C@H]1CC[C@@H]2[C@]1(C)CCC\C2=C/C=C1/C[C@@H](O)C[C@H](O)C1=C,0,Launched,vitamin D receptor agonist,noncancer
doxepin,CN(C)CC\C=C1\c2ccccc2COc2ccccc12,0,Launched,histamine receptor antagonist,Unknown
enocitabine,CCCCCCCCCCCCCCCCCCCCCC(=O)Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1,1,Launched,DNA synthesis inhibitor,chemo
PHA-848125,CNC(=O)c1nn(C)c-2c1C(C)(C)Cc1cnc(Nc3ccc(cc3)N3CCN(C)CC3)nc-21,1,Phase 2,"CDK inhibitor, growth factor receptor inhibitor",targeted cancer
MK-0354,C1Cc2[nH]nc(-c3nnn[nH]3)c2C1,0,Phase 2,niacin receptor agonist,noncancer
GR-103691,COc1ccccc1N1CCN(CCCCNC(=O)c2ccc(cc2)-c2ccc(cc2)C(C)=O)CC1,0,Preclinical,dopamine receptor antagonist,noncancer
butaclamol,CC(C)(C)[C@@]1(O)CCN2C[C@@H]3c4ccccc4CCc4cccc([C@H]2C1)c34,0,Phase 2,dopamine receptor antagonist,noncancer
RN-1734,CC(C)NCCN(C(C)C)S(=O)(=O)c1ccc(Cl)cc1Cl,1,Preclinical,TRPV antagonist,noncancer
vandetanib,COc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OCC1CCN(C)CC1,1,Launched,"EGFR inhibitor, RET tyrosine kinase inhibitor, VEGFR inhibitor",targeted cancer
pyrithione-zinc,O1[n+]2ccccc2S[Zn]11O[n+]2ccccc2S1,1,Launched,ATP synthase inhibitor,Unknown
LY3023414,CO[C@@H](C)Cn1c2c(cnc3ccc(cc23)-c2cncc(c2)C(C)(C)O)n(C)c1=O,1,Phase 2,"PI3K inhibitor, mTOR inhibitor",targeted cancer
taurine,NCCS(O)(=O)=O,1,Launched,antioxidant,noncancer
INH1,Cc1ccc(c(C)c1)-c1csc(NC(=O)c2ccccc2)n1,1,Preclinical,Hec1 inhibitor,targeted cancer
geniposide,COC(=O)C1=CO[C@@H](O[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)[C@H]2[C@@H]1CC=C2CO,0,Preclinical,GLP receptor agonist,targeted cancer
PF-04457845,FC(F)(F)c1ccc(Oc2cccc(C=C3CCN(CC3)C(=O)Nc3cccnn3)c2)nc1,1,Phase 2,FAAH inhibitor,noncancer
SB-202190,Oc1ccc(cc1)-c1nc(c([nH]1)-c1ccncc1)-c1ccc(F)cc1,0,Preclinical,p38 MAPK inhibitor,targeted cancer
telcagepant,Fc1cccc([C@@H]2CC[C@@H](NC(=O)N3CCC(CC3)n3c4cccnc4[nH]c3=O)C(=O)N(CC(F)(F)F)C2)c1F,0,Phase 3,calcitonin antagonist,noncancer
metrizamide,CN(C(C)=O)c1c(I)c(NC(C)=O)c(I)c(C(=O)N[C@H]2C(O)O[C@H](CO)[C@@H](O)[C@@H]2O)c1I,0,Launched,radiopaque medium,noncancer
phenylbutyrate,OC(=O)CCCc1ccccc1,0,Launched,HDAC inhibitor,noncancer
NVP-AEW541,Nc1ncnc2n(cc(-c3cccc(OCc4ccccc4)c3)c12)[C@@H]1C[C@H](CN2CCC2)C1,1,Preclinical,IGF-1 inhibitor,targeted cancer
hesperidin,COc1ccc(cc1O)[C@@H]1CC(=O)c2c(O)cc(O[C@@H]3O[C@H](CO[C@@H]4O[C@@H](C)[C@H](O)[C@@H](O)[C@H]4O)[C@@H](O)[C@H](O)[C@H]3O)cc2O1,0,Launched,flavanone glycoside,noncancer
propafenone,CCCNCC(O)COc1ccccc1C(=O)CCc1ccccc1,0,Launched,antiarrhythmic,noncancer
AM-580,CC1(C)CCC(C)(C)c2cc(ccc12)C(=O)Nc1ccc(cc1)C(O)=O,1,Preclinical,retinoid receptor agonist,targeted cancer
chlorproguanil,CC(C)NC(=N)NC(=N)Nc1ccc(Cl)c(Cl)c1,0,Launched,dihydrofolate reductase inhibitor,noncancer
CCT128930,NC1(Cc2ccc(Cl)cc2)CCN(CC1)c1ncnc2[nH]ccc12,1,Preclinical,AKT inhibitor,targeted cancer
faropenem,CC(O)C1C2SC(C3CCCO3)=C(N2C1=O)C(O)=O,0,Launched,lactamase inhibitor,noncancer
nepicastat,NCc1c[nH]c(=S)n1[C@H]1CCc2c(F)cc(F)cc2C1,0,Phase 2,dopamine beta hydroxylase inhibitor,noncancer
YM022,Cc1cccc(NC(=O)N[C@@H]2N=C(c3ccccc3)c3ccccc3N(CC(=O)c3ccccc3C)C2=O)c1,0,Phase 2,CCK receptor antagonist,noncancer
uridine,OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1ccc(=O)[nH]c1=O,1,Phase 2,dopamine receptor agonist,noncancer
U-104,NS(=O)(=O)c1ccc(NC(=O)Nc2ccc(F)cc2)cc1,0,Preclinical,carbonic anhydrase inhibitor,targeted cancer
penicillin-v-potassium,CC1(C)S[C@@H]2[C@H](NC(=O)COc3ccccc3)C(=O)N2[C@H]1C(O)=O,0,Launched,bacterial cell wall synthesis inhibitor,noncancer
nornicotine,C1CNC(C1)c1cccnc1,0,Preclinical,acetylcholine receptor agonist,noncancer
canrenone,C[C@]12CCC3C(C=CC4=CC(=O)CC[C@]34C)C1CC[C@@]21CCC(=O)O1,1,Withdrawn,mineralocorticoid receptor antagonist,noncancer
phentolamine,Cc1ccc(cc1)N(CC1=NCCN1)c1cccc(O)c1,0,Launched,adrenergic receptor antagonist,noncancer
digitoxigenin,C[C@]12CC[C@H]3[C@@H](CC[C@@H]4C[C@@H](O)CC[C@]34C)[C@@]1(O)CC[C@@H]2C1=CC(=O)OC1,1,Preclinical,ATPase inhibitor,Unknown
UNC0631,COc1cc2c(NC3CCN(CC4CCCCC4)CC3)nc(nc2cc1OCCCN1CCCCC1)N1CCCN(CC1)C(C)C,1,Preclinical,histone lysine methyltransferase inhibitor,targeted cancer
talipexole,Nc1nc2CCN(CC=C)CCc2s1,0,Launched,"adrenergic receptor agonist, dopamine receptor agonist",noncancer
volasertib,CC[C@H]1N(C(C)C)c2nc(Nc3ccc(cc3OC)C(=O)N[C@H]3CC[C@@H](CC3)N3CCN(CC4CC4)CC3)ncc2N(C)C1=O,1,Phase 3,PLK inhibitor,targeted cancer
dimethindene-(S)-(+),C[C@@H](C1=C(CCN(C)C)Cc2ccccc12)c1ccccn1,0,Preclinical,acetylcholine receptor antagonist,noncancer
"4-acetyl-1,1-dimethylpiperazinium",CC(=O)N1CC[N+](C)(C)CC1,0,Preclinical,acetylcholine receptor agonist,noncancer
RS-100329,Cc1c[nH]c(=O)n(CCCN2CCN(CC2)c2ccccc2OCC(F)(F)F)c1=O,0,Preclinical,adrenergic receptor antagonist,noncancer
SB-239063,COc1nccc(n1)-c1c(ncn1[C@H]1CC[C@H](O)CC1)-c1ccc(F)cc1,1,Preclinical,p38 MAPK inhibitor,noncancer
MLN0128,CC(C)n1nc(-c2ccc3oc(N)nc3c2)c2c(N)ncnc12,1,Phase 2,mTOR inhibitor,targeted cancer
chlorpyrifos,CCOP(=S)(OCC)Oc1nc(Cl)c(Cl)cc1Cl,1,Launched,acetylcholinesterase inhibitor,noncancer
cisplatin,N[Pt](N)(Cl)Cl,1,Launched,"DNA alkylating agent, DNA synthesis inhibitor",chemo
triptolide,CC(C)[C@]12O[C@H]1[C@@H]1O[C@]11[C@]3(O[C@H]3C[C@H]3C4=C(CC[C@]13C)C(=O)OC4)[C@@H]2O,1,Phase 3,RNA polymerase inhibitor,Unknown
GW-1929,CN(CCOc1ccc(CC(Nc2ccccc2C(=O)c2ccccc2)C(O)=O)cc1)c1ccccn1,0,Preclinical,PPAR receptor agonist,noncancer
vicriviroc,COC[C@H](N1CCN(C[C@@H]1C)C1(C)CCN(CC1)C(=O)c1c(C)ncnc1C)c1ccc(cc1)C(F)(F)F,0,Phase 3,CC chemokine receptor antagonist,targeted cancer
TH-302,Cn1c(COP(=O)(NCCBr)NCCBr)cnc1[N+]([O-])=O,1,Phase 3,DNA alkylating agent,chemo
tridihexethyl,CC[N+](CC)(CC)CCC(O)(C1CCCCC1)c1ccccc1,0,Launched,acetylcholine receptor antagonist,noncancer
GW-9662,[O-][N+](=O)c1ccc(Cl)c(c1)C(=O)Nc1ccccc1,0,Preclinical,PPAR receptor antagonist,noncancer
tolterodine,CC(C)N(CC[C@H](c1ccccc1)c1cc(C)ccc1O)C(C)C,0,Launched,acetylcholine receptor antagonist,noncancer
rosmarinic-acid,OC(=O)[C@@H](Cc1ccc(O)c(O)c1)OC(=O)\C=C\c1ccc(O)c(O)c1,0,Launched,GABA transaminase inhibitor,targeted cancer
5-hydroxytryptophan,NC(Cc1c[nH]c2ccc(O)cc12)C(O)=O,0,Launched,neurotransmitter,noncancer
XL388,Cc1c(F)c(ccc1C(=O)N1CCOc2ccc(cc2C1)-c1ccc(N)nc1)S(C)(=O)=O,1,Preclinical,mTOR inhibitor,targeted cancer
SC-12267,COc1cccc(c1)-c1ccc(NC(=O)C2=C(CCC2)C(O)=O)c(F)c1,1,Phase 2,dihydroorotate dehydrogenase inhibitor,noncancer
cortisone,C[C@]12CC(=O)C3C(CCC4=CC(=O)CC[C@]34C)C1CC[C@]2(O)C(=O)CO,0,Launched,glucocorticoid receptor agonist,noncancer
olmutinib,CN1CCN(CC1)c1ccc(Nc2nc(Oc3cccc(NC(=O)C=C)c3)c3sccc3n2)cc1,0,Launched,"EGFR inhibitor, Bruton's tyrosine kinase (BTK) inhibitor",targeted cancer
lorediplon,CN(C(C)=O)c1cc(ccc1F)-c1ccnc2c(cnn12)C(=O)c1cccs1,0,Phase 2,GABA receptor modulator,noncancer
acetohexamide,CC(=O)c1ccc(cc1)S(=O)(=O)NC(=O)NC1CCCCC1,0,Launched,ATP channel blocker,noncancer
albendazole,CCCSc1ccc2[nH]c(NC(=O)OC)nc2c1,1,Launched,tubulin polymerization inhibitor,noncancer
valethamate,CCC(C)C(C(=O)OCC[N+](C)(CC)CC)c1ccccc1,0,Launched,acetylcholine receptor antagonist,noncancer
clemizole,Clc1ccc(Cn2c(CN3CCCC3)nc3ccccc23)cc1,0,Launched,HCV inhibitor,noncancer
lonidamine,OC(=O)c1nn(Cc2ccc(Cl)cc2Cl)c2ccccc12,0,Launched,glucokinase inhibitor,targeted cancer
aloxistatin,CCOC(=O)[C@H]1O[C@@H]1C(=O)N[C@@H](CC(C)C)C(=O)NCCC(C)C,0,Phase 3,protease inhibitor,noncancer
NSC-405020,CCCC(C)NC(=O)c1ccc(Cl)c(Cl)c1,0,Preclinical,matrix metalloprotease inhibitor,noncancer
bretazenil,CC(C)(C)OC(=O)c1ncn-2c1[C@@H]1CCCN1C(=O)c1c(Br)cccc-21,0,Phase 2,GABA benzodiazepine site receptor partial agonist,Unknown
JNJ-37822681,Fc1ccc(CN2CCC(CC2)Nc2ccc(nn2)C(F)(F)F)cc1F,0,Phase 2,dopamine receptor antagonist,noncancer
thiomersal,CC[Hg]Sc1ccccc1C(O)=O,1,Launched,other antibiotic,noncancer
adoprazine,Fc1ccc(cc1)-c1cncc(CN2CCN(CC2)c2cccc3OCCOc23)c1,0,Phase 2,"dopamine receptor antagonist, serotonin receptor agonist",noncancer
tiotropium,C[N+]1(C)[C@H]2C[C@@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)C(O)(c1cccs1)c1cccs1,0,Launched,acetylcholine receptor antagonist,Unknown
GBR-13069,Fc1ccc(cc1)C(OCCN1CCN(C\C=C\c2ccccc2)CC1)c1ccc(F)cc1,0,Preclinical,dopamine uptake inhibitor,noncancer
isepamicin,CN[C@@H]1[C@@H](O)[C@@H](O[C@H]2[C@@H](C[C@H](N)[C@@H](O[C@H]3O[C@H](CN)[C@@H](O)[C@H](O)[C@H]3O)[C@@H]2O)NC(=O)[C@@H](O)CN)OC[C@]1(C)O,0,Launched,protein synthesis inhibitor,noncancer
melperone,CC1CCN(CCCC(=O)c2ccc(F)cc2)CC1,0,Launched,"dopamine receptor antagonist, serotonin receptor antagonist",noncancer
arctigenin,COc1cc(C[C@@H]2[C@@H](Cc3ccc(OC)c(OC)c3)COC2=O)ccc1O,1,Preclinical,MEK inhibitor,targeted cancer
carbamazepine,NC(=O)N1c2ccccc2C=Cc2ccccc12,0,Launched,carboxamide antiepileptic,noncancer
RS-67506,COc1cc(N)c(Cl)cc1C(=O)CCC1CCN(CCNS(C)(=O)=O)CC1,1,Preclinical,serotonin receptor partial agonist,noncancer
vesamicol,O[C@@H]1CCCC[C@H]1N1CCC(CC1)c1ccccc1,0,Preclinical,acetylcholinesterase inhibitor,noncancer
phthalylsulfathiazole,OC(=O)c1ccccc1C(=O)Nc1ccc(cc1)S(=O)(=O)Nc1nccs1,0,Launched,dihydropteroate synthetase inhibitor,noncancer
arbutin,OC[C@H]1O[C@@H](Oc2ccc(O)cc2)[C@H](O)[C@@H](O)[C@@H]1O,0,Phase 2/Phase 3,melanin inhibitor,noncancer
EVP4593,Nc1ccc2ncnc(NCCc3ccc(Oc4ccccc4)cc3)c2c1,1,Preclinical,NFkB pathway inhibitor,noncancer
L-ergothioneine,C[N+](C)(C)[C@@H](Cc1c[nH]c(=S)[nH]1)C(O)=O,0,Phase 2,free radical scavenger,noncancer
stemregenin-1,CC(C)n1cnc2c(NCCc3ccc(O)cc3)nc(nc12)-c1csc2ccccc12,1,Preclinical,aryl hydrocarbon receptor antagonist,noncancer
oxaliplatin,O=C1O[Pt]2(N[C@@H]3CCCC[C@H]3N2)OC1=O,1,Launched,DNA inhibitor,chemo
levofloxacin,C[C@H]1COc2c(N3CCN(C)CC3)c(F)cc3c2n1cc(C(O)=O)c3=O,0,Launched,bacterial DNA gyrase inhibitor,noncancer
pantethine,CC(C)(CO)[C@@H](O)C(=O)NCCC(=O)NCCSSCCNC(=O)CCNC(=O)[C@H](O)C(C)(C)CO,0,Launched,coenzyme A precursor,noncancer
TAK-733,Cn1c2ncn(C[C@@H](O)CO)c(=O)c2c(Nc2ccc(I)cc2F)c(F)c1=O,1,Phase 1,MEK inhibitor,targeted cancer
VX-702,NC(=O)N(c1ccc(C(N)=O)c(n1)-c1ccc(F)cc1F)c1c(F)cccc1F,1,Phase 2,p38 MAPK inhibitor,noncancer
ciclesonide,CC(C)C(=O)OCC(=O)[C@@]12O[C@@H](O[C@@H]1C[C@H]1[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@]21C)C1CCCCC1,1,Launched,glucocorticoid receptor agonist,noncancer
SKLB1002,COc1cc2ncnc(Sc3nnc(C)s3)c2cc1OC,0,Preclinical,VEGFR inhibitor,targeted cancer
tobramycin,NC[C@H]1O[C@H](O[C@@H]2[C@@H](N)C[C@@H](N)[C@H](O[C@H]3O[C@H](CO)[C@@H](O)[C@H](N)[C@H]3O)[C@H]2O)[C@H](N)C[C@@H]1O,0,Launched,bacterial 30S ribosomal subunit inhibitor,noncancer
chlormidazole,Cc1nc2ccccc2n1Cc1ccc(Cl)cc1,1,Launched,fungal lanosterol demethylase inhibitor,noncancer
corosolic-acid,C[C@@H]1CC[C@@]2(CC[C@]3(C)C(=CC[C@@H]4[C@@]5(C)C[C@@H](O)[C@H](O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]2[C@H]1C)C(O)=O,0,Phase 2,"PKC inhibitor, protein tyrosine kinase inhibitor",targeted cancer
ethosuximide,CCC1(C)CC(=O)NC1=O,0,Launched,succinimide antiepileptic,noncancer
FK-33-824,C[C@H](NC(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)NCC(=O)N(C)[C@@H](Cc1ccccc1)C(=O)N[C@H](CO)CCS(C)=O,0,Phase 2,opioid receptor agonist,noncancer
butamben,CCCCOC(=O)c1ccc(N)cc1,1,Withdrawn,sodium channel blocker,noncancer
IKK-2-inhibitor-V,Oc1ccc(Cl)cc1C(=O)Nc1cc(cc(c1)C(F)(F)F)C(F)(F)F,1,Phase 1,"IKK inhibitor, NFkB pathway inhibitor",targeted cancer
acitazanolast,OC(=O)C(=O)Nc1cccc(c1)-c1nnn[nH]1,0,Launched,mediator release inhibitor,Unknown
idasanutlin,COc1cc(ccc1NC(=O)[C@@H]1N[C@@H](CC(C)(C)C)[C@@](C#N)([C@H]1c1cccc(Cl)c1F)c1ccc(Cl)cc1F)C(O)=O,1,Phase 3,MDM inhibitor,targeted cancer
dimethisoquin,CCCCc1cc2ccccc2c(OCCN(C)C)n1,1,Launched,local anesthetic,noncancer
harmane,Cc1nccc2c3ccccc3[nH]c12,0,Preclinical,monoamine oxidase inhibitor,noncancer
chlorpropamide,CCCNC(=O)NS(=O)(=O)c1ccc(Cl)cc1,1,Launched,ATP channel blocker,noncancer
LDN-212854,C1CN(CCN1)c1ccc(cc1)-c1cnc2c(cnn2c1)-c1cccc2ncccc12,1,Preclinical,bone morphogenic protein inhibitor,noncancer
tiopronin,CC(S)C(=O)NCC(O)=O,0,Launched,"chelating agent, reducing agent",noncancer
CH223191,Cc1cc(ccc1NC(=O)c1ccnn1C)\N=N\c1ccccc1C,0,Preclinical,aryl hydrocarbon receptor antagonist,noncancer
anethole-trithione,COc1ccc(cc1)-c1cc(=S)ss1,0,Launched,glutathione transferase stimulant,noncancer
pregnenolone-succinate,CC(=O)[C@H]1CCC2C3CC=C4C[C@H](CC[C@]4(C)C3CC[C@]12C)OC(=O)CCC(O)=O,0,Preclinical,GABA receptor negative allosteric modulator,noncancer
menadione-bisulfite,CC1(CC(=O)c2ccccc2C1=O)S(O)(=O)=O,0,Phase 2,vitamin K,noncancer
bergenin,COc1c(O)cc2C(=O)O[C@@H]3[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]3c2c1O,0,Preclinical,interleukin inhibitor,noncancer
topotecan,CC[C@@]1(O)C(=O)OCc2c1cc1-c3nc4ccc(O)c(CN(C)C)c4cc3Cn1c2=O,1,Launched,topoisomerase inhibitor,chemo
oxybenzone,COc1ccc(C(=O)c2ccccc2)c(O)c1,0,Launched,lipase inhibitor,noncancer
betrixaban,COc1ccc(NC(=O)c2ccc(cc2)C(=N)N(C)C)c(c1)C(=O)Nc1ccc(Cl)cn1,0,Launched,coagulation factor inhibitor,noncancer
nemonapride,CNc1cc(OC)c(cc1Cl)C(=O)N[C@@H]1CCN(Cc2ccccc2)[C@@H]1C.CNc1cc(OC)c(cc1Cl)C(=O)N[C@H]1CCN(Cc2ccccc2)[C@H]1C,1,Launched,dopamine receptor antagonist,Unknown
peruvoside,CO[C@H]1[C@@H](O)C(C)O[C@@H](O[C@H]2CC[C@@]3(C=O)[C@H](CC[C@@H]4[C@@H]3CC[C@]3(C)[C@H](CC[C@]43O)C3=CC(=O)OC3)C2)C1O,1,Phase 1,cardiac glycoside,Unknown
axitinib,CNC(=O)c1ccccc1Sc1ccc2c(\C=C\c3ccccn3)n[nH]c2c1,1,Launched,"PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor",targeted cancer
LY2801653,Cc1ccc(C(=O)Nc2ccc(Oc3cc4cnn(C)c4cc3-c3cn[nH]c3)c(F)c2)c(=O)n1-c1ccc(F)cc1,1,Phase 2,MET inhibitor,targeted cancer
doconexent-ethyl-ester,CCOC(=O)CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CC,0,Launched,omega 3 fatty acid stimulant,noncancer
testosterone-enanthate,CCCCCCC(=O)O[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C,0,Launched,androgen receptor agonist,noncancer
AS-703026,OC[C@@H](O)CNC(=O)c1ccncc1Nc1ccc(I)cc1F,1,Phase 2,MEK inhibitor,targeted cancer
ramatroban,OC(=O)CCn1c2CC[C@H](Cc2c2ccccc12)NS(=O)(=O)c1ccc(F)cc1,1,Launched,prostanoid receptor antagonist,noncancer
xaliproden,FC(F)(F)c1cccc(c1)C1=CCN(CCc2ccc3ccccc3c2)CC1,0,Phase 3,serotonin receptor agonist,targeted cancer
N-salicoylaminophenol,Oc1ccc(NC(=O)c2ccccc2O)cc1,0,Preclinical,ribonucleotide reductase inhibitor,noncancer
naftidrofuryl,CCN(CC)CCOC(=O)C(CC1CCCO1)Cc1cccc2ccccc12,1,Launched,adrenergic receptor antagonist,noncancer
methicillin,COc1cccc(OC)c1C(=O)N[C@H]1[C@H]2SC(C)(C)[C@@H](N2C1=O)C(O)=O,0,Launched,bacterial cell wall synthesis inhibitor,noncancer
azeliragon,CCCCc1nc(cn1-c1ccc(Oc2ccc(Cl)cc2)cc1)-c1ccc(OCCCN(CC)CC)cc1,0,Phase 3,RAGE receptor antagonist,noncancer
GDC-0980,C[C@H](O)C(=O)N1CCN(Cc2sc3c(nc(nc3c2C)-c2cnc(N)nc2)N2CCOCC2)CC1,1,Phase 2,"mTOR inhibitor, PI3K inhibitor",targeted cancer
forodesine,OC[C@H]1N[C@H]([C@H](O)[C@@H]1O)c1c[nH]c2c1[nH]cnc2=O,1,Phase 2,purinergic receptor antagonist,targeted cancer
oxazepam,OC1N=C(c2ccccc2)c2cc(Cl)ccc2NC1=O,1,Launched,GABA benzodiazepine site receptor agonist,noncancer
IOWH032,Oc1c(Br)cc(cc1Br)-c1noc(n1)C(=O)NCc1ccc(Oc2ccccc2)cc1,1,Phase 2,CFTR channel antagonist,noncancer
taselisib,CC(C)n1nc(C)nc1-c1cn2CCOc3cc(ccc3-c2n1)-c1cnn(c1)C(C)(C)C(N)=O,1,Phase 3,PI3K inhibitor,targeted cancer
gambogic-acid,CC(C)=CCC[C@@]1(C)Oc2c(CC=C(C)C)c3O[C@@]45[C@H]6C[C@@H](C=C4C(=O)c3c(O)c2C=C1)C(=O)[C@]5(C\C=C(\C)C(O)=O)OC6(C)C,1,Phase 2,caspase activator,targeted cancer
N20C,NC(=O)CNCCC(c1ccccc1)c1ccccc1,0,Preclinical,glutamate receptor antagonist,targeted cancer
cloxyquin,Oc1ccc(Cl)c2cccnc12,0,Preclinical,potassium channel activator,noncancer
benzthiazide,NS(=O)(=O)c1cc2c(cc1Cl)N=C(CSCc1ccccc1)NS2(=O)=O,0,Launched,carbonic anhydrase inhibitor,noncancer
nintedanib,COC(=O)c1ccc2c(NC(=O)\C2=C(/Nc2ccc(cc2)N(C)C(=O)CN2CCN(C)CC2)c2ccccc2)c1,1,Launched,"FGFR inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor",targeted cancer
bavisant,O=C(N1CCN(CC1)C1CC1)c1ccc(CN2CCOCC2)cc1,0,Phase 2,histamine receptor antagonist,noncancer
amuvatinib,S=C(NCc1ccc2OCOc2c1)N1CCN(CC1)c1ncnc2c3ccccc3oc12,0,Phase 2,"FLT3 inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, RAD51 inhibitor, RET tyrosine kinase inhibitor",targeted cancer
erythromycin,CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O,0,Launched,NFkB pathway inhibitor,noncancer
BIBU-1361,CCN(CC)CC1CCN(CC1)c1ncc2ncnc(Nc3ccc(F)c(Cl)c3)c2n1,1,Preclinical,EGFR inhibitor,targeted cancer
MBX-2982,CCc1cnc(nc1)N1CCC(CC1)c1nc(COc2ccc(cc2)-n2cnnn2)cs1,0,Phase 2,glucose dependent insulinotropic receptor agonist,noncancer
mitiglinide,OC(=O)[C@H](CC(=O)N1C[C@H]2CCCC[C@H]2C1)Cc1ccccc1,0,Launched,insulin secretagogue,noncancer
VS-4718,CNC(=O)c1ccccc1Nc1cc(Nc2ccc(cc2OC)N2CCOCC2)ncc1C(F)(F)F,1,Phase 1,focal adhesion kinase inhibitor,targeted cancer
ZM-323881,Cc1cc(F)c(Nc2ncnc3cc(OCc4ccccc4)ccc23)cc1O,0,Preclinical,VEGFR inhibitor,targeted cancer
levonorgestrel,CC[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@H]34)[C@@H]1CC[C@@]2(O)C#C,1,Launched,"estrogen receptor agonist, glucocorticoid receptor antagonist, progesterone receptor agonist, progesterone receptor antagonist",noncancer
tosufloxacin,NC1CCN(C1)c1nc2n(cc(C(O)=O)c(=O)c2cc1F)-c1ccc(F)cc1F,0,Launched,bacterial DNA gyrase inhibitor,noncancer
ergonovine,CC(CO)NC(=O)C1CN(C)[C@@H]2Cc3c[nH]c4cccc(C2=C1)c34,0,Launched,"adrenergic receptor agonist, serotonin receptor agonist",noncancer
nifursol,Oc1c(cc(cc1[N+]([O-])=O)[N+]([O-])=O)C(=O)N\N=C\c1ccc(o1)[N+]([O-])=O,0,Launched,bacterial DNA inhibitor,noncancer
dioxybenzone,COc1ccc(C(=O)c2ccccc2O)c(O)c1,0,Preclinical,topical sunscreen agent,noncancer
flibanserin,FC(F)(F)c1cccc(c1)N1CCN(CCn2c3ccccc3[nH]c2=O)CC1,0,Launched,serotonin receptor agonist,noncancer
loratadine,CCOC(=O)N1CCC(CC1)=C1c2ccc(Cl)cc2CCc2cccnc12,0,Launched,histamine receptor antagonist,noncancer
captopril,C[C@H](CS)C(=O)N1CCC[C@H]1C(O)=O,0,Launched,angiotensin converting enzyme inhibitor,noncancer
cefpiramide,Cc1cc(O)c(cn1)C(=O)N[C@@H](C(=O)N[C@H]1[C@H]2SCC(CSc3nnnn3C)=C(N2C1=O)C(O)=O)c1ccc(O)cc1,1,Launched,bacterial cell wall synthesis inhibitor,noncancer
molsidomine,CCOC(=O)Nc1c[n+](no1)N1CCOCC1,0,Launched,guanylate cyclase stimulant,noncancer
PFK-015,O=C(\C=C\c1ccc2ccccc2n1)c1ccncc1,1,Phase 1,phosphofructokinase inhibitor,targeted cancer
tramiprosate,NCCCS(O)(=O)=O,0,Phase 3,beta amyloid protein neurotoxicity inhibitor,noncancer
mibampator,CC(C)S(=O)(=O)NC[C@H](C)c1ccc(cc1)-c1ccc(CCNS(C)(=O)=O)cc1,1,Phase 2,glutamate receptor modulator,noncancer
AM-1241,CN1CCCCC1Cn1cc(C(=O)c2cc(ccc2I)[N+]([O-])=O)c2ccccc12,0,Preclinical,cannabinoid receptor agonist,noncancer
vernakalant,COc1ccc(CCO[C@@H]2CCCC[C@H]2N2CC[C@@H](O)C2)cc1OC,0,Launched,potassium channel blocker,noncancer
flindokalner,COc1ccc(Cl)cc1[C@]1(F)C(=O)Nc2cc(ccc12)C(F)(F)F,0,Phase 3,potassium channel agonist,noncancer
fidaxomicin,CC[C@H]1\C=C(C)/[C@@H](O)C\C=C\C=C(CO[C@@H]2O[C@H](C)[C@@H](OC(=O)c3c(O)c(Cl)c(O)c(Cl)c3CC)[C@H](O)[C@@H]2OC)\C(=O)O[C@H](C\C=C(C)\C=C(C)[C@H]1O[C@@H]1OC(C)(C)[C@@H](OC(=O)C(C)C)[C@H](O)[C@H]1O)[C@@H](C)O,0,Launched,RNA polymerase inhibitor,noncancer
etafenone,CCN(CC)CCOc1ccccc1C(=O)CCc1ccccc1,0,Launched,calcium channel blocker,noncancer
homatropine-methylbromide,C[N+]1(C)C2CC[C@H]1C[C@H](C2)OC(=O)C(O)c1ccccc1,0,Launched,acetylcholine receptor antagonist,Unknown
bakuchiol,CC(C)=CCC[C@@](C)(C=C)\C=C\c1ccc(O)cc1,0,Phase 2,DNA polymerase inhibitor,noncancer
lomefloxacin,CCn1cc(C(O)=O)c(=O)c2cc(F)c(N3CCNC(C)C3)c(F)c12,1,Launched,bacterial DNA gyrase inhibitor,noncancer
arglabin,CC1=CC[C@]23O[C@@]2(C)CC[C@@H]2[C@H](OC(=O)C2=C)[C@@H]13,0,Launched,farnesyltransferase inhibitor,targeted cancer
VU0357121,CCCCOc1ccc(cc1)C(=O)Nc1ccc(F)cc1F,0,Preclinical,glutamate receptor positive allosteric modulator,noncancer
polydatin,OC[C@H]1O[C@@H](Oc2cc(O)cc(\C=C\c3ccc(O)cc3)c2)[C@H](O)[C@@H](O)[C@@H]1O,1,Phase 2,ICAM1 expression inhibitor,noncancer
cabergoline,CCNC(=O)N(CCCN(C)C)C(=O)[C@@H]1C[C@H]2[C@@H](Cc3c[nH]c4cccc2c34)N(CC=C)C1,0,Launched,dopamine receptor agonist,noncancer
clobenpropit,Clc1ccc(CNC(=N)SCCCc2c[nH]cn2)cc1,0,Preclinical,histamine receptor antagonist,noncancer
anpirtoline,Clc1cccc(SC2CCNCC2)n1,0,Phase 1,serotonin receptor agonist,noncancer
INCB-024360,NS(=O)(=O)NCCNc1nonc1\C(Nc1ccc(F)c(Br)c1)=N\O,0,Phase 2,"indoleamine 2,3-dioxygenase inhibitor",targeted cancer
BRL-15572,OC(CN1CCN(CC1)c1cccc(Cl)c1)C(c1ccccc1)c1ccccc1,0,Preclinical,serotonin receptor antagonist,noncancer
GW-0742,Cc1nc(sc1CSc1ccc(OCC(O)=O)c(C)c1)-c1ccc(c(F)c1)C(F)(F)F,0,Preclinical,PPAR receptor agonist,noncancer
elafibranor,CSc1ccc(cc1)C(=O)\C=C\c1cc(C)c(OC(C)(C)C(O)=O)c(C)c1,0,Phase 3,PPAR receptor agonist,targeted cancer
LB42708,Brc1ccc(Cn2cncc2Cn2cc(C(=O)N3CCOCC3)c(c2)-c2cccc3ccccc23)cc1,1,Preclinical,farnesyltransferase inhibitor,targeted cancer
finafloxacin,OC(=O)c1cn(C2CC2)c2c(C#N)c(N3C[C@@H]4NCCO[C@H]4C3)c(F)cc2c1=O,1,Launched,bacterial DNA gyrase inhibitor,noncancer
ceritinib,CC(C)Oc1cc(C2CCNCC2)c(C)cc1Nc1ncc(Cl)c(Nc2ccccc2S(=O)(=O)C(C)C)n1,0,Launched,ALK tyrosine kinase receptor inhibitor,Unknown
SB-258585,COc1ccc(NS(=O)(=O)c2ccc(I)cc2)cc1N1CCN(C)CC1,0,Preclinical,serotonin receptor antagonist,noncancer
MK-5108,OC(=O)[C@@]1(Cc2cccc(Nc3nccs3)n2)CC[C@@H](CC1)Oc1cccc(Cl)c1F,1,Phase 1,Aurora kinase inhibitor,targeted cancer
FR-180204,Nc1[nH]nc2nnc(cc12)-c1c(nn2ccccc12)-c1ccccc1,0,Preclinical,MAP kinase inhibitor,targeted cancer
fostamatinib,COc1cc(Nc2ncc(F)c(Nc3ccc4OC(C)(C)C(=O)N(COP(O)(O)=O)c4n3)n2)cc(OC)c1OC,0,Launched,SYK inhibitor,noncancer
spiperone,Fc1ccc(cc1)C(=O)CCCN1CCC2(CC1)N(CNC2=O)c1ccccc1,0,Launched,dopamine receptor antagonist,noncancer
memantine,CC12CC3CC(C)(C1)CC(N)(C3)C2,0,Launched,glutamate receptor antagonist,noncancer
NSC-4644,CC(=C)[C@@H]1CC[C@]2(CO)CC[C@]3(C)[C@H](CC[C@@H]4[C@@]5(C)CC[C@H](O)C(C)(C)[C@@H]5CC[C@@]34C)[C@@H]12,0,Phase 2,"ACAT inhibitor, sterol regulatory element binding protein (SREBP) inhibitor",noncancer
medronic-acid,OP(O)(=O)CP(O)(O)=O,0,Launched,bone resorption inhibitor,noncancer
L-Arginine,N[C@H](CCCNC(N)=N)C(O)=O,0,Launched,nitric oxide precursor,noncancer
SB-328437,COC(=O)[C@H](Cc1ccc(cc1)[N+]([O-])=O)NC(=O)c1cccc2ccccc12,0,Preclinical,CCR antagonist,noncancer
tolnaftate,CN(C(=S)Oc1ccc2ccccc2c1)c1cccc(C)c1,0,Launched,fungal squalene epoxidase inhibitor,noncancer
eliglustat,CCCCCCCC(=O)N[C@H](CN1CCCC1)[C@H](O)c1ccc2OCCOc2c1,0,Launched,Glycosyl transferase inhibitor,noncancer
tioconazole,Clc1sccc1COC(Cn1ccnc1)c1ccc(Cl)cc1Cl,0,Launched,sterol demethylase inhibitor,Unknown
apalutamide,CNC(=O)c1ccc(cc1F)N1C(=S)N(C(=O)C11CCC1)c1cnc(C#N)c(c1)C(F)(F)F,0,Launched,androgen receptor antagonist,targeted cancer
bemegride,CCC1(C)CC(=O)NC(=O)C1,0,Launched,chemoreceptor agonist,noncancer
mdivi-1,COc1cc(c(Cl)cc1Cl)-n1c(=S)[nH]c2ccccc2c1=O,0,Preclinical,dynamin inhibitor,Unknown
SC-9,Clc1cccc2c(cccc12)S(=O)(=O)NCCCCCCc1ccccc1,0,Preclinical,protein tyrosine kinase activator,noncancer
10-deacetylbaccatin,CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@]1(C)[C@@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](O)C(C)=C([C@@H](O)C1=O)C2(C)C,1,Preclinical,antitumor agent,targeted cancer
PHA-680632,CCc1cccc(CC)c1NC(=O)N1Cc2[nH]nc(NC(=O)c3ccc(cc3)N3CCN(C)CC3)c2C1,1,Preclinical,Aurora kinase inhibitor,targeted cancer
S-14506,COc1ccc2cccc(N3CCN(CCNC(=O)c4ccc(F)cc4)CC3)c2c1,0,Preclinical,serotonin receptor agonist,noncancer
metirosine,C[C@](N)(Cc1ccc(O)cc1)C(O)=O,0,Launched,tyrosine hydroxylase inhibitor,noncancer
AEG3482,NS(=O)(=O)c1nn2cc(nc2s1)-c1ccccc1,1,Preclinical,HSP inducer,targeted cancer
NU-7441,O=c1cc(oc2c(cccc12)-c1cccc2c3ccccc3sc12)N1CCOCC1,0,Preclinical,DNA dependent protein kinase inhibitor,targeted cancer
ethotoin,CCN1C(=O)NC(C1=O)c1ccccc1,0,Launched,hydantoin antiepileptic,noncancer
piromidic-acid,CCn1cc(C(O)=O)c(=O)c2cnc(nc12)N1CCCC1,0,Phase 2,bacterial DNA gyrase inhibitor,noncancer
avanafil,COc1ccc(CNc2nc(ncc2C(=O)NCc2ncccn2)N2CCC[C@H]2CO)cc1Cl,1,Launched,phosphodiesterase inhibitor,noncancer
"L-655,708",CCOC(=O)c1ncn-2c1[C@@H]1CCCN1C(=O)c1cc(OC)ccc-21,0,Preclinical,GABA receptor inverse agonist,noncancer
bortezomib,CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O,1,Launched,"NFkB pathway inhibitor, proteasome inhibitor",Unknown
flumatinib,CN1CCN(Cc2ccc(cc2C(F)(F)F)C(=O)Nc2cnc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1,1,Phase 3,Bcr-Abl kinase inhibitor,targeted cancer
CNX-774,CNC(=O)c1cc(Oc2ccc(Nc3ncc(F)c(Nc4cccc(NC(=O)C=C)c4)n3)cc2)ccn1,1,Preclinical,Bruton's tyrosine kinase (BTK) inhibitor,targeted cancer
AZ-628,Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1,1,Preclinical,RAF inhibitor,targeted cancer
gallamine-triethiodide,CC[N+](CC)(CC)CCOc1cccc(OCC[N+](CC)(CC)CC)c1OCC[N+](CC)(CC)CC,0,Launched,acetylcholine receptor antagonist,noncancer
loteprednol,CCOC(=O)O[C@@]1(CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@]12C)C(=O)OCCl,0,Launched,"glucocorticoid receptor agonist, phospholipase inhibitor",noncancer
VER-49009,CCNC(=O)c1[nH]nc(c1-c1ccc(OC)cc1)-c1cc(Cl)c(O)cc1O,1,Preclinical,HSP inhibitor,targeted cancer
A-366,COc1cc2c(cc1OCCCN1CCCC1)N=C(N)C21CCC1,0,Preclinical,histone lysine methyltransferase inhibitor,targeted cancer
bromocriptine,CC(C)C[C@@H]1N2C(=O)[C@](NC(=O)[C@H]3CN(C)[C@@H]4Cc5c(Br)[nH]c6cccc(C4=C3)c56)(O[C@@]2(O)[C@@H]2CCCN2C1=O)C(C)C,0,Launched,dopamine receptor agonist,noncancer
zolpidem,CN(C)C(=O)Cc1c(nc2ccc(C)cn12)-c1ccc(C)cc1,0,Launched,benzodiazepine receptor agonist,noncancer
SKF-81297,Oc1cc2C(CNCCc2c(Cl)c1O)c1ccccc1,0,Preclinical,dopamine receptor agonist,noncancer
BRL-52537,Clc1ccc(CC(=O)N2CCCCC2CN2CCCC2)cc1Cl,0,Preclinical,opioid receptor agonist,noncancer
VTP-27999,CN[C@H](CNC(=O)N1CCC[C@H](C1)[C@@H](OCCNC(=O)OC)c1cccc(Cl)c1)C[C@H]1CCCOC1,1,Phase 1,renin inhibitor,noncancer
iodoquinol,Oc1c(I)cc(I)c2cccnc12,0,Launched,antiseptic,noncancer
A66,Cc1nc(NC(=O)N2CCC[C@H]2C(N)=O)sc1-c1csc(n1)C(C)(C)C,0,Preclinical,PI3K inhibitor,targeted cancer
finasteride,CC(C)(C)NC(=O)[C@H]1CC[C@H]2[C@@H]3CC[C@H]4NC(=O)C=C[C@]4(C)[C@H]3CC[C@]12C,0,Launched,5 alpha reductase inhibitor,noncancer
KU-60019,C[C@H]1CN(CC(=O)Nc2ccc3Sc4c(Cc3c2)cccc4-c2cc(=O)cc(o2)N2CCOCC2)C[C@@H](C)O1,0,Preclinical,ATM kinase inhibitor,noncancer
anguidine,CC(=O)OC[C@]12CCC(C)=C[C@H]1O[C@@H]1[C@H](O)[C@@H](OC(C)=O)[C@@]2(C)[C@@]11CO1,1,Phase 2,protein synthesis inhibitor,Unknown
L-365260,CN1c2ccccc2C(=N[C@@H](NC(=O)Nc2cccc(C)c2)C1=O)c1ccccc1,0,Phase 2,CCK receptor antagonist,noncancer
frentizole,COc1ccc2nc(NC(=O)Nc3ccccc3)sc2c1,1,Phase 1,immunosuppressant,noncancer
sacubitril,CCOC(=O)[C@H](C)C[C@@H](Cc1ccc(cc1)-c1ccccc1)NC(=O)CCC(O)=O,0,Launched,neprilysin inhibitor,noncancer
fleroxacin,CN1CCN(CC1)c1c(F)cc2c(c1F)n(CCF)cc(C(O)=O)c2=O,1,Launched,topoisomerase inhibitor,noncancer
4-HQN,Oc1ncnc2ccccc12,0,Preclinical,PARP inhibitor,targeted cancer
centpropazine,CCC(=O)c1ccc(OCC(O)CN2CCN(CC2)c2ccccc2)cc1,0,Phase 3,inositol monophosphatase inhibitor,noncancer
merimepodib,COc1cc(NC(=O)Nc2cccc(CNC(=O)O[C@H]3CCOC3)c2)ccc1-c1cnco1,1,Phase 2,inosine monophosphate dehydrogenase inhibitor,noncancer
ropinirole,CCCN(CCC)CCc1cccc2NC(=O)Cc12,0,Launched,dopamine receptor agonist,noncancer
tolamolol,Cc1ccccc1OCC(O)CNCCOc1ccc(cc1)C(N)=O,0,Phase 3,adrenergic receptor antagonist,noncancer
TG100-115,Nc1nc(N)c2nc(-c3cccc(O)c3)c(nc2n1)-c1cccc(O)c1,1,Phase 1/Phase 2,PI3K inhibitor,targeted cancer
JQ1-(+),Cc1sc-2c(c1C)C(=N[C@@H](CC(=O)OC(C)(C)C)c1nnc(C)n-21)c1ccc(Cl)cc1,1,Preclinical,bromodomain inhibitor,targeted cancer
chlorpromazine,CN(C)CCCN1c2ccccc2Sc2ccc(Cl)cc12,0,Launched,dopamine receptor antagonist,noncancer
terutroban,Cc1ccc2C[C@@H](CCc2c1CCC(O)=O)NS(=O)(=O)c1ccc(Cl)cc1,0,Phase 3,prostanoid receptor antagonist,noncancer
dazoxiben,OC(=O)c1ccc(OCCn2ccnc2)cc1,0,Phase 2,thromboxane synthase inhibitor,noncancer
ethinyl-estradiol,C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CC[C@@]2(O)C#C,1,Launched,"estrogen receptor agonist, estrogenic hormone",noncancer
AZD1981,CC(=O)Nc1cccc2n(CC(O)=O)c(C)c(Sc3ccc(Cl)cc3)c12,0,Phase 2,CRTH receptor antagonist,noncancer
itraconazole,CCC(C)n1ncn(-c2ccc(cc2)N2CCN(CC2)c2ccc(OC[C@H]3CO[C@@](Cn4cncn4)(O3)c3ccc(Cl)cc3Cl)cc2)c1=O,1,Launched,cytochrome P450 inhibitor,noncancer
terbutaline,CC(C)(C)NCC(O)c1cc(O)cc(O)c1,1,Launched,adrenergic receptor agonist,noncancer
PCA-4248,COC(=O)C1=C(C)NC(C)=C(C1C)C(=O)OCCSc1ccccc1,0,Phase 1,platelet activating factor receptor antagonist,noncancer
protriptyline,CNCCCC1c2ccccc2C=Cc2ccccc12,0,Launched,tricyclic antidepressant,noncancer
pirenperone,Cc1nc2ccccn2c(=O)c1CCN1CCC(CC1)C(=O)c1ccc(F)cc1,1,Preclinical,serotonin receptor antagonist,noncancer
XBD173,CCN(Cc1ccccc1)C(=O)Cn1c2nc(ncc2n(C)c1=O)-c1ccccc1,1,Phase 2,benzodiazepine receptor ligand,noncancer
tranexamic-acid,NC[C@H]1CC[C@@H](CC1)C(O)=O,0,Launched,"antifibrinolytic, plasminogen activator inhibitor",noncancer
quiflapon,CC(C)(C)Sc1c(CC(C)(C)C(O)=O)n(Cc2ccc(Cl)cc2)c2ccc(OCc3ccc4ccccc4n3)cc12,0,Phase 2,leukotriene synthesis inhibitor,Unknown
SC-560,COc1ccc(cc1)-n1nc(cc1-c1ccc(Cl)cc1)C(F)(F)F,0,Preclinical,cyclooxygenase inhibitor,targeted cancer
mepazine,CN1CCCC(CN2c3ccccc3Sc3ccccc23)C1,0,Phase 2,MALT1 inhibitor (JH),targeted cancer
tyrphostin-AG-99,NC(=O)C(=C\c1ccc(O)c(O)c1)\C#N,1,Preclinical,tyrosine kinase inhibitor,targeted cancer
cinchonidine,O[C@@H]([C@@H]1C[C@@H]2CC[N@]1C[C@@H]2C=C)c1ccnc2ccccc12,0,Phase 1,P glycoprotein inhibitor,targeted cancer
zanamivir,CC(=O)N[C@@H]1[C@@H](NC(N)=N)C=C(O[C@H]1[C@H](O)[C@H](O)CO)C(O)=O,0,Launched,neuraminidase inhibitor,noncancer
albuterol,CC(C)(C)NCC(O)c1ccc(O)c(CO)c1,0,Launched,adrenergic receptor agonist,noncancer
sulfaphenazole,Nc1ccc(cc1)S(=O)(=O)Nc1ccnn1-c1ccccc1,0,Launched,dihydropteroate synthetase inhibitor,noncancer
ABT-751,COc1ccc(cc1)S(=O)(=O)Nc1cccnc1Nc1ccc(O)cc1,1,Phase 2,tubulin polymerization inhibitor,chemo
erythrosine,OC(=O)c1ccccc1-c1c2cc(I)c(O)c(I)c2oc2c(I)c(=O)c(I)cc12,0,Preclinical,coloring agent,noncancer
KI-8751,COc1cc2nccc(Oc3ccc(NC(=O)Nc4ccc(F)cc4F)c(F)c3)c2cc1OC,1,Preclinical,"KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor",targeted cancer
resatorvid,CCOC(=O)C1=CCCC[C@H]1S(=O)(=O)Nc1ccc(F)cc1Cl,1,Phase 3,toll-like receptor antagonist,noncancer
paracetamol,CC(=O)Nc1ccc(O)cc1,0,Launched,cyclooxygenase inhibitor,noncancer
bruceantin,COC(=O)[C@]12OC[C@@]34[C@H]1[C@@H](OC(=O)\C=C(/C)C(C)C)C(=O)O[C@@H]3C[C@H]1C(C)C(=O)C(=O)C[C@]1(C)[C@H]4[C@@H](O)[C@@H]2O,1,Phase 2,protein synthesis inhibitor,Unknown
TCS2002,Cc1nnc(o1)-c1ccc2occ(-c3ccc(cc3)S(C)=O)c2c1,0,Preclinical,glycogen synthase kinase inhibitor,noncancer
chlorphensin-carbamate,NC(=O)OCC(O)COc1ccc(Cl)cc1,0,Preclinical,muscle relaxant,noncancer
vinburnine,CC[C@@]12CCCN3CCc4c([C@H]13)n(C(=O)C2)c1ccccc41,0,Launched,adrenergic receptor antagonist,noncancer
mosapride,CCOc1cc(N)c(Cl)cc1C(=O)NCC1CN(Cc2ccc(F)cc2)CCO1,0,Launched,serotonin receptor agonist,noncancer
venlafaxine,COc1ccc(cc1)C(CN(C)C)C1(O)CCCCC1,0,Launched,"adrenergic inhibitor, norepinephrine reuptake inhibitor, serotonin-norepinephrine reuptake inhibitor (SNRI)",noncancer
AJ76-(+),CCCN[C@@H]1CCc2c(OC)cccc2[C@@H]1C,0,Preclinical,dopamine receptor antagonist,noncancer
